[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"The First Hospital of Jilin University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":620},{"pageToken":4,"total":5,"offset":6,"count":7,"results":8},null,62,0,25,[9,41,71,90,118,142,164,187,205,226,250,278,304,322,344,373,399,420,446,470,495,524,550,574,599],{"id":10,"slug":11,"hasResults":12,"nctId":13,"briefTitle":14,"officialTitle":15,"acronym":16,"eligibilityCriteria":17,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":21,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":25,"conditions":26,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":29,"lastUpdatePostDateStruct":30,"startDateStruct":33,"completionDateStruct":35,"leadSponsor":37,"locationsCount":40},"100635979","risk-factors-and-predictive-model-for-inflammatory-polyps-in-ureteral-stones-100635979",false,"NCT07559721","Risk Factors and Predictive Model for Inflammatory Polyps in Ureteral Stones","Risk Factors and Development of a Predictive Model for Stone-Associated Inflammatory Ureteral Polyps: A Retrospective Cohort Study With Prospective Validation","UROLITH-POLYP","Inclusion Criteria:\n\n* Patients aged 18 years or older undergoing ureteroscopic surgery for ureteral calculi at the First Hospital of Jilin University.\n* Complete clinical and imaging data available.\n\nExclusion Criteria:\n\n* Patients with bilateral ureteral calculi.\n* Patients with preoperative nephrostomy or indwelling ureteral stent.\n* Patients with a history of ureteral or bladder cancer.\n* Patients with congenital ureteral anomalies or previous ureteral surgery.\n* Patients with severe coagulation disorders or contraindications to ureteroscopy.\n* Patients unable to provide informed consent.","ALL","18 Years","80 Years",{"count":22,"type":23},779,"ESTIMATED","OBSERVATIONAL","This is a single-center, observational study including a retrospective cohort and a prospective validation cohort. The study aims to identify independent risk factors for inflammatory ureteral polyps in patients with ureteral calculi and develop a preoperative predictive model. The retrospective part will analyze clinical and imaging data of patients treated at the First Hospital of Jilin University between 2018 and 2025. The prospective part is currently recruiting participants to validate the model. The primary outcome is the intraoperative diagnosis of inflammatory ureteral polyps.",[27],"Ureteral Calculi","RECRUITING","2026-06-04",{"date":31,"type":32},"2026-06-08","ACTUAL",{"date":34,"type":32},"2018-01-01",{"date":36,"type":23},"2027-02-01",{"name":38,"class":39},"The First Hospital of Jilin University","OTHER",1,{"id":42,"slug":43,"hasResults":12,"nctId":44,"briefTitle":45,"officialTitle":46,"acronym":4,"eligibilityCriteria":47,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":48,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":50,"conditions":51,"keywords":55,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":63,"lastUpdatePostDateStruct":64,"startDateStruct":66,"completionDateStruct":68,"leadSponsor":70,"locationsCount":4},"100638271","a-subharmonic-aided-pressure-estimate-technology-for-prediction-of-response-to-systemic-therapy-in-gastric-cancer-liver-metastases-100638271","NCT07581730","A Subharmonic-Aided Pressure Estimate Technology for Prediction of Response to Systemic Therapy in Gastric Cancer Liver Metastases","A Prospective Study of a Subharmonic-Aided Pressure Estimate Technology for Early Prediction of Response to Systemic Therapy in Gastric Cancer Liver Metastases","Inclusion Criteria:\n\n* Age ≥ 18 years.\n* Histologically or radiologically confirmed, initially diagnosed and have not undergone any treatment gastric liver metastasis (GCLM).\n* Lesion size ≤ 6 cm (preferably located adjacent to major anatomical structures such as large vessels or bile ducts).\n* Lesion depth ≤ 10 cm on ultrasound imaging.\n* Planned to receive guideline-recommended first-line systemic therapy.\n* The target lesion has not undergone any prior systemic or local treatment, including surgery, ablation, embolization, targeted therapy, or investigational agents, before enrollment.\n* Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n* Inability to cooperate with contrast-enhanced ultrasound or subharmonic imaging examinations (e.g., dyspnea when lying supine or excessive out-of-plane motion).\n* Know or suspected allergy to the contrast agent or other contraindications to its use.\n* Target lesion not previously evaluated or managed according to standard systemic treatment protocols.\n* Clinically unstable condition, advanced-stage disease, or patients with an unpredictable clinical course that may affect treatment tolerance or follow-up.\n* Pregnant or breastfeeding women. 6.Inability to understand or comply with the study protocol, including the requirement to complete follow-up visits and examinations.",{"count":49,"type":23},107,"Gastric cancer is a common type of cancer that often spreads to the liver. When cancer spreads to the liver, treatment becomes very difficult. Many patients will undergo chemotherapy to shrink the tumor. Currently, doctors use CT or MRI scans to assess the effect of chemotherapy, but these examinations usually take about 2 months to show changes in the size of the tumor.\n\nThe purpose of this study is to test whether a special type of ultrasound technology called \"contrast-enhanced subharmonic ultrasound\" can help doctors determine earlier whether chemotherapy is effective compared to conventional scans. This ultrasound detection does not use radiation and can display the blood perfusion status inside liver tumors. We will observe the changes in blood flow perfusion inside the tumor before the start of treatment and after 1-2 chemotherapy cycles to see if these changes can predict whether chemotherapy will be effective in the future.\n\nIf this test is effective, it will help doctors adjust the treatment plan more quickly, which may improve the treatment effect for gastric cancer patients whose cancer cells have spread to the liver, and also help identify patients who are not responding to chemotherapy as early as possible, reducing the side effects and economic burden of patients.",[52,53,54],"Liver Neoplasms","Gastric Cancer (GC)","Gastric Cancer Metastatic to Liver",[56,57,58,59,60,61],"Gastric cancer liver metastasis","Contrast-enhanced ultrasound","Subharmonic imaging","Chemotherapy response prediction","Early treatment response","Perfusion imaging","NOT_YET_RECRUITING","2026-05-18",{"date":65,"type":32},"2026-05-20",{"date":67,"type":23},"2026-05-01",{"date":69,"type":23},"2027-12-01",{"name":38,"class":39},{"id":72,"slug":73,"hasResults":12,"nctId":74,"briefTitle":75,"officialTitle":75,"acronym":4,"eligibilityCriteria":76,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":77,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":79,"conditions":80,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":83,"lastUpdatePostDateStruct":84,"startDateStruct":85,"completionDateStruct":87,"leadSponsor":89,"locationsCount":4},"100638933","a-comparative-study-on-the-diagnostic-efficacy-of-ultrasound-contrast-li-rads-grading-and-the-german-esculap-standards-for-the-diagnosis-of-recurrent-hepatic-mass-lesions-after-hepatocellular-carcinoma-surgery-100638933","NCT07600346","A Comparative Study on the Diagnostic Efficacy of Ultrasound Contrast LI-RADS Grading and the German ESCULAP Standards for the Diagnosis of Recurrent Hepatic Mass Lesions After Hepatocellular Carcinoma Surgery","Inclusion Criteria:\n\n* (1) At least 18 years old; (2) Has a previous history of liver cell cancer surgery or ablation, and has a newly developed liver lesion this time; (3) The new lesion completed a complete contrast-enhanced ultrasound examination within two weeks before the final diagnosis, and the dynamic imaging data is completely preserved; (4) The new lesion has a clear pathological or clinical diagnosis.\n\nExclusion Criteria:\n\n* (1) The quality of contrast-enhanced ultrasound images is poor, making it impossible to assess the critical phases; (2) New lesions that have been treated locally or systemically.",{"count":78,"type":23},105,"Hepatocellular carcinoma (HCC) is the sixth most common malignant tumor worldwide, with a significantly increased incidence among patients with liver diseases. Even if HCC can be treated by surgical resection and ablation, the 5-year recurrence rate is as high as 50-70%. The Liver Imaging Reporting and Data System (LI-RADS), released by the American College of Radiology (ACR), is a classification management system specifically designed to evaluate liver lesions in high-risk HCC patients. Since its release in 2011, the CT\u002FMRI LI-RADS has been updated to the 2018 version. Subsequently, the CEUS LI-RADS was introduced in 2016 and updated in 2017. The CEUS LI-RADS standard has relatively high specificity but lacks sensitivity. The ESCULAP (Erlanger Synopsis of Contrast-enhanced Ultrasound for Liver lesion Assessment in Patients at Risk) standard proposed by Schellhaas et al. in Germany has high sensitivity in diagnosing HCC in patients with liver diseases . However, there is currently a lack of research on the diagnostic efficacy of these two standards for the re-discovery of liver space-occupying lesions in patients with a history of HCC. This study aims to compare the diagnostic efficacy of the two standards for recurrent HCC in patients with a history of HCC.",[81,82],"Hepatocellular Carcinoma (HCC) Prognosis","Contrast-enhanced Ultrasound","2026-05-14",{"date":65,"type":32},{"date":86,"type":23},"2026-05-30",{"date":88,"type":23},"2027-05-30",{"name":38,"class":39},{"id":91,"slug":92,"hasResults":12,"nctId":93,"briefTitle":94,"officialTitle":95,"acronym":96,"eligibilityCriteria":97,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":98,"enrollmentInfo":99,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":101,"conditions":102,"keywords":104,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":110,"lastUpdatePostDateStruct":111,"startDateStruct":113,"completionDateStruct":115,"leadSponsor":117,"locationsCount":40},"100637782","hybrid-deep-learning-integrating-multimodal-ceus-and-enhanced-mri-to-optimize-early-stage-hcc-treatment-decisions-100637782","NCT07582419","Hybrid Deep Learning Integrating Multimodal CEUS and Enhanced MRI to Optimize Early-Stage HCC Treatment Decisions","Hybrid Deep Learning Models Based on Multimodal CEUS and Enhanced MRI Can Optimize Treatment Decisions for Early-stage Hepatocellular Carcinoma","HDL-CEUS-MRI","Inclusion Criteria:\n\n1. Preoperative enhanced imaging examination or pathological diagnosis is HCC;\n2. CNLC Stage I, IIa, Child-Pugh Class A\u002FB;\n3. A single tumor with a diameter ≤ 5 cm or 2-3 tumors, with the maximum diameter ≤ 3 cm;\n4. Perform liver resection surgery or MWA surgery treatment;\n5. MRI and\u002For CEUS examinations performed within one month before surgery\n\nExclusion Criteria:\n\n1：There is already extrahepatic metastasis or the presence of other malignant tumors;\n\n2: History of other treatments prior to surgery;\n\n3: Incomplete preoperative ultrasound contrast and\u002For MRI imaging data, with images missing or unclear;\n\n4: Missing postoperative follow-up data","85 Years",{"count":100,"type":23},1424,"This study aims to address the issue of a lack of individualized basis for selecting liver resection (LH) or microwave ablation (MWA) in early-stage hepatocellular carcinoma (HCC) patients to reduce the early recurrence rate (≤2 years). Given that existing machine learning-based recurrence prediction studies have failed to guide the optimal treatment plan selection, and that multidisciplinary consultations rely on guidelines (universality) and experience (subjectivity) which have their limitations, we propose to utilize artificial intelligence (AI), specifically the advantages of multimodal deep learning technology (which outperforms traditional machine learning by integrating complementary information to provide more accurate predictions), to establish a hybrid deep learning model that integrates contrast-enhanced ultrasound (CEUS) and enhanced magnetic resonance imaging (MRI) features. This model will predict the probability of early recurrence (ER≤2 years) in patients and, based on this, recommend LH or MWA as the optimal first treatment option for newly diagnosed early HCC patients to optimize individualized treatment decisions.",[103],"Hepatocellular Carcinoma (HCC)",[105,106,107,108,109],"Multimodal","CEUS","Enhanced MRI","Treatment Decisions","hepatocellular carcinoma","2026-05-07",{"date":112,"type":32},"2026-05-12",{"date":114,"type":23},"2026-04-30",{"date":116,"type":23},"2027-10-30",{"name":38,"class":39},{"id":119,"slug":120,"hasResults":12,"nctId":121,"briefTitle":122,"officialTitle":122,"acronym":4,"eligibilityCriteria":123,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":124,"targetDuration":4,"studyType":125,"phases":126,"briefSummary":128,"conditions":129,"keywords":132,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":4},"100640212","a-prospective-study-of-a-subharmonic-aided-pressure-estimate-technology-for-early-prediction-of-response-to-systemic-therapy-in-colorectal-cancer-liver-metastases-100640212","NCT07583381","A Prospective Study of a Subharmonic-Aided Pressure Estimate Technology for Early Prediction of Response to Systemic Therapy in Colorectal Cancer Liver Metastases","Inclusion Criteria:\n\n1. Age ≥ 18 years.\n2. Histologically or radiologically confirmed, initially diagnosed and have not undergone any treatment colorectal liver metastasis (CRLM).\n3. Lesion size ≤ 6 cm (preferably located adjacent to major anatomical structures such as large vessels or bile ducts).\n4. Lesion depth ≤ 10 cm on ultrasound imaging.\n5. Planned to receive guideline-recommended first-line systemic therapy.\n6. The target lesion has not undergone any prior systemic or local treatment, including surgery, ablation, embolization, targeted therapy, or investigational agents, before enrollment.\n7. Willingness to provide written informed consent.\n\nExclusion Criteria:\n\n1. Inability to cooperate with contrast-enhanced ultrasound or subharmonic imaging examinations (e.g., dyspnea when lying supine or excessive out-of-plane motion).\n2. Know or suspected allergy to the contrast agent or other contraindications to its use.\n3. Target lesion not previously evaluated or managed according to standard systemic treatment protocols.\n4. Clinically unstable condition, advanced-stage disease, or patients with an unpredictable clinical course that may affect treatment tolerance or follow-up.\n5. Pregnant or breastfeeding women.\n6. Inability to understand or comply with the study protocol, including the requirement to complete follow-up visits and examinations.",{"count":49,"type":23},"INTERVENTIONAL",[127],"NA","Colorectal cancer is a common type of cancer that often spreads to the liver. When cancer spreads to the liver, treatment becomes very difficult. Many patients will undergo chemotherapy to shrink the tumor. Currently, doctors use CT or MRI scans to assess the effect of chemotherapy, but these examinations usually take about 2 months to show changes in the size of the tumor.\n\nThe purpose of this study is to test whether a special type of ultrasound technology called \"contrast-enhanced subharmonic ultrasound\" can help doctors determine earlier whether chemotherapy is effective compared to conventional scans. This ultrasound detection does not use radiation and can display the blood perfusion status inside liver tumors. We will observe the changes in blood flow perfusion inside the tumor before the start of treatment and after 1-2 chemotherapy cycles to see if these changes can predict whether chemotherapy will be effective in the future.\n\nIf this test is effective, it will help doctors adjust the treatment plan more quickly, which may improve the treatment effect for colon cancer patients whose cancer cells have spread to the liver, and also help identify patients who are not responding to chemotherapy as early as possible, reducing the side effects and economic burden of patients.",[130,52,131],"Colorectal Liver Metastasis","Colorectal Neoplasms",[133,57,58,59,60,61],"Colorectal cancer liver metastasis","2026-05-06",{"date":136,"type":32},"2026-05-13",{"date":138,"type":23},"2026-06-01",{"date":140,"type":23},"2027-12-31",{"name":38,"class":39},{"id":143,"slug":144,"hasResults":12,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":12,"sex":149,"minAge":19,"maxAge":150,"enrollmentInfo":151,"targetDuration":153,"studyType":24,"phases":4,"briefSummary":154,"conditions":155,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":67,"lastUpdatePostDateStruct":158,"startDateStruct":159,"completionDateStruct":161,"leadSponsor":163,"locationsCount":4},"100637051","ultrasound-guided-core-needle-biopsy-to-assess-sensitivity-and-specificity-of-axillary-lymph-node-metastasis-in-breast-cancer-100637051","NCT07573657","Ultrasound-Guided Core Needle Biopsy to Assess Sensitivity and Specificity of Axillary Lymph Node Metastasis in Breast Cancer","Sensitivity and Specificity of Ultrasound-Guided Core Needle Biopsy in Evaluating Axillary Lymph Node Metastasis in Breast Cancer","Inclusion Criteria:\n\n1. Age ≥18 years and \\\u003C70 years;\n2. Histologically confirmed primary breast cancer;\n3. Underwent ultrasound examination to assess axillary lymph node metastasis status.\n\nExclusion Criteria:\n\n1. Presence of other malignancies (e.g., lymphoma, lung cancer, thyroid cancer, etc., with axillary metastasis);\n2. Pregnant or lactating women;\n3. Previous receipt of neoadjuvant radiotherapy or chemotherapy;\n4. Lymph node metastasis status not confirmed by pathology, or time interval between ultrasound examination and pathological confirmation exceeding 6 weeks.","FEMALE","70 Years",{"count":152,"type":23},200,"10 Days","This study plans to find the most suitable lymph node cortex thickness and abnormal lymph node features to define suspicious lymph nodes. Then, ultrasound-guided core needle biopsy of axillary lymph nodes will be done, aiming to provide some guidance for the biopsy.",[156,157],"Lymphatic Metastasis","Breast Neoplasms",{"date":110,"type":32},{"date":160,"type":23},"2026-10-01",{"date":162,"type":23},"2028-10-01",{"name":38,"class":39},{"id":165,"slug":166,"hasResults":12,"nctId":167,"briefTitle":168,"officialTitle":168,"acronym":4,"eligibilityCriteria":169,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":170,"targetDuration":4,"studyType":125,"phases":172,"briefSummary":173,"conditions":174,"keywords":177,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":179,"lastUpdatePostDateStruct":180,"startDateStruct":182,"completionDateStruct":184,"leadSponsor":186,"locationsCount":40},"100604620","the-diagnostic-value-of-subharmonic-imaging-technology-combined-with-liver-stiffness-and-platelet-count-for-high-risk-esophageal-and-gastric-varices-in-patients-with-liver-cirrhosis-100604620","NCT07151885","The Diagnostic Value of Subharmonic Imaging Technology Combined With Liver Stiffness and Platelet Count for High-risk Esophageal and Gastric Varices in Patients With Liver Cirrhosis","Inclusion Criteria:\n\n* ① Be at least 18 years old② Clinically diagnosed as liver cirrhosis (based on medical history, physical signs, laboratory tests, imaging or liver biopsy)③ Underwent a gastroscopy④ The informed consent form has been signed\n\nExclusion Criteria:\n\n* ① Previous EV bleeding or having received TIPS\u002F endoscopic treatment.② History of concurrent liver cancer, portal vein thrombosis, and splenectomy.③ Having used drugs that affect platelet count, liver function or coagulation function in the body within one week, and having a recent history of blood product infusion.",{"count":171,"type":23},380,[127],"To evaluate the diagnostic value of the combined model of subharmonic-assisted pressure estimation (SHAPE), liver stiffness (LSM), and platelet count (PLT) for high-risk esophageal and gastric varices (HRV)",[175,176],"Liver Cirrhosis","Esophageal and Gastric Varices",[175,176,178],"Subharmonic Aided Pressure Estimation","2026-04-29",{"date":181,"type":32},"2026-05-05",{"date":183,"type":32},"2025-08-31",{"date":185,"type":23},"2028-07-31",{"name":38,"class":39},{"id":188,"slug":189,"hasResults":12,"nctId":190,"briefTitle":191,"officialTitle":192,"acronym":193,"eligibilityCriteria":194,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":195,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":197,"conditions":198,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":200,"startDateStruct":201,"completionDateStruct":202,"leadSponsor":204,"locationsCount":4},"100636130","ursl-angle-for-predicting-intraoperative-conversion-100636130","NCT07561684","URSL Angle for Predicting Intraoperative Conversion","An Exploratory Predictive Study on the Intraoperative Change of Surgical Methods in Transurethral Ureteroscopy for Ureteral Calculi","URSL-PREDICT","Inclusion Criteria:\n\n1. Age \\> 18 years at the time of surgery, without restriction based on sex, ethnicity, or occupation.\n2. Preoperative imaging confirmation of unilateral, solitary, or unilateral multiple ureteral calculi. In cases of ipsilateral multiple stones, the calculus deemed primarily responsible for obstruction or designated as the principal surgical target shall serve as the index stone.\n3. Planned and attempted transurethral ureteroscopic lithotripsy as the initial treatment modality.\n4. Availability of preoperative thin-slice (section thickness ≤ 1.25 mm) computed tomography urography or non-contrast CT of the urinary tract in native Digital Imaging and Communications in Medicine (DICOM) format, of sufficient diagnostic quality to permit multiplanar reconstruction and precise morphometric analysis. Image data must be complete and free from substantial motion or beam-hardening artifact that would preclude accurate delineation of ureteral anatomy.\n\nExclusion Criteria:\n\n* 1.Absence of preoperative CT imaging performed at the participating institution; missing, corrupted, or irretrievable DICOM data; or suboptimal image quality that precludes reliable ureteral segmentation and measurement.\n\n  2.Incomplete inpatient medical records lacking essential demographic or baseline clinical data; operative notes containing insufficient procedural detail to definitively ascertain whether intraoperative conversion occurred or to adjudicate the specific etiology thereof.\n\n  3.Prior ipsilateral percutaneous nephrostomy tube placement or ureteral stent indwelling for any indication before the index URSL procedure.\n\n  4.Calculi situated at anatomically distinct locations, specifically the ureteropelvic junction or the ureteral orifice.\n\n  5.Antecedent ipsilateral ureteral surgery (e.g., ureteral reimplantation, prior ureteroscopic lithotripsy) or history of urinary diversion (e.g., ileal conduit). Such patients are excluded because surgical alteration of native ureteral anatomy would confound the morphometric assumptions underlying URSL angle determination.",{"count":196,"type":23},2200,"This international multicenter retrospective cohort study aims to externally validate the URSL Predictive Angle, a novel CT-derived morphometric parameter, as an imaging biomarker for predicting intraoperative conversion risk during transurethral ureteroscopic lithotripsy (URSL) for ureteral calculi.\n\nIntraoperative conversion is defined as the unanticipated abandonment of the planned endoscopic approach due to unfavorable ureteral anatomy or stone impaction, necessitating recourse to open ureterolithotomy, laparoscopic ureterolithotomy, or ureteral stent placement with planned staged secondary intervention. Such conversions are associated with protracted operative duration, heightened anesthetic exposure, and increased physical, psychological, and financial burdens on patients.\n\nThe URSL Predictive Angle is a geometric parameter derived from preoperative coronal CT reformations that quantifies the degree of local ureteral angulation induced by an impacted calculus. Preliminary single-center data demonstrated robust predictive fidelity of this metric with an area under the ROC curve of 0.861 and an optimal discriminatory threshold of 131.8° yielding a sensitivity of 82% and a specificity of 88%.\n\nThis study will enroll eligible patients from multiple domestic and international tertiary care hospitals who underwent URSL for ureteral calculi between January 1, 2018, and December 31, 2025. The primary outcome is intraoperative conversion of surgical approach. The predictive performance of the URSL angle will be evaluated using ROC curve analysis with AUC calculation. Propensity score matching and multivariable logistic regression will be employed to address potential confounding.\n\nThis study is registered as a patient registry with a cohort model. Data collection is retrospective, involving abstraction from electronic medical records, operative logs, and PACS. A waiver of informed consent has been requested based on the retrospective design, minimal risk determination, stringent anonymization procedures, and impracticability of obtaining individual consent.",[27],"2026-04-24",{"date":67,"type":32},{"date":138,"type":23},{"date":203,"type":23},"2026-09-30",{"name":38,"class":39},{"id":206,"slug":207,"hasResults":12,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":213,"targetDuration":4,"studyType":125,"phases":215,"briefSummary":217,"conditions":218,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":199,"lastUpdatePostDateStruct":220,"startDateStruct":221,"completionDateStruct":223,"leadSponsor":225,"locationsCount":40},"100635982","phase-2-new-second-line-combo-therapy-for-mss-metastatic-colorectal-cancer-100635982","NCT07559760","New Second-Line Combo Therapy for MSS Metastatic Colorectal Cancer","A Prospective Study of Levoleucovorin\u002F5-FU Co-Infusion Combined With Liposomal Irinotecan ±Cetuximab\u002FBevacizumab as Second-Line Therapy for MSS Metastatic Colorectal Cancer","Inclusion Criteria:\n\n1. Male or female, aged 18-75 years.\n2. Histologically or cytologically confirmed colorectal adenocarcinoma.\n3. Unresectable, MSS-type metastatic colorectal cancer that has failed or is intolerant to first-line standard oxaliplatin plus fluoropyrimidine ± targeted therapy.\n\n   * Failure definition: progression during or within 3 months after completing first-line oxaliplatin\u002Ffluoropyrimidine ± targeted therapy.\n   * Adjuvant setting: progression\u002Frecurrence during or within 6 months of completing adjuvant oxaliplatin-based chemotherapy\u002Fchemoradiation counts as first-line failure.\n4. At least one measurable lesion by RECIST 1.1.\n5. ECOG performance status 0-1.\n6. Expected survival ≥ 3 months.\n7. Adequate organ function within 14 days before enrollment (no transfusion or growth-factor support):\n\n   * Hematology: Hb ≥ 90 g\u002FL; WBC ≥ 3.0 × 10⁹\u002FL; ANC ≥ 1.5 × 10⁹\u002FL; PLT ≥ 90 × 10⁹\u002FL.\n   * Coagulation: INR ≤ 1.5 × ULN; APTT ≤ 1.5 × ULN (stable anticoagulation at therapeutic range allowed).\n   * Renal: Creatinine clearance ≥ 50 mL\u002Fmin (Cockcroft-Gault).\n   * Hepatic:\n   * No liver mets: TBIL ≤ 1.5 × ULN, ALT ≤ 2.5 × ULN, AST ≤ 2.5 × ULN.\n   * Liver mets: TBIL ≤ 2 × ULN, ALT ≤ 5 × ULN, AST ≤ 5 × ULN.\n   * Cardiac: LVEF ≥ 50 %.\n8. Voluntary written informed consent; willing and able to comply with study procedures and follow-up.\n9. WOCBP must have a negative serum\u002Furine pregnancy test within 3 days before first study-dose (Cycle 1 Day 1).\n10. All subjects (men and women) with reproductive potential must use a highly effective contraceptive method (annual failure rate \\\u003C 1 %) from screening until 120 days after the last dose of investigational product or 180 days after the last chemotherapy dose, whichever is later.\n\nExclusion Criteria:\n\n1. Prior exposure to topoisomerase-I inhibitors or their analogues in first-line therapy.\n2. Documented hypersensitivity to any study drug or its excipients.\n3. Pregnant or breast-feeding women.\n4. Toxicities from prior therapy not resolved to CTCAE v5.0 Grade ≤ 1 (except alopecia or other toxicities deemed by the investigator to pose no safety risk).\n5. Any anti-cancer therapy (chemotherapy, radiotherapy, biologics, targeted therapy, immunotherapy, etc.) within 4 weeks before first study-dose; major surgery (excluding biopsy) within 4 weeks that has not fully healed.\n6. Severe psychiatric or psychological disorders that could compromise compliance.\n7. Clinically significant cardiovascular disease:\n\n   * Severe\u002Funstable angina, symptomatic congestive heart failure (NYHA ≥ II), clinically significant arrhythmia requiring treatment, arterial thrombosis, acute coronary syndrome, MI, cerebrovascular accident (including TIA) or other Grade ≥ 3 CV event within 6 months prior to first dose.\n   * QTcF ≥ 450 ms (men) or ≥ 470 ms (women) on resting 12-lead ECG.\n8. Infection-related:\n\n   * Active infection or unexplained fever \\> 38.5 °C on screening or dosing day (tumor fever allowed at investigator's discretion).\n   * Serious infection (CTCAE Grade 3, e.g., pneumonia, bacteremia) requiring hospitalization within 4 weeks.\n   * Active pulmonary inflammation on baseline imaging or need for systemic antibiotics (prophylactic antibiotics permitted).\n9. Known HIV-positive, active hepatitis B, or hepatitis C:\n\n   * HBsAg or HBcAb positive: HBV DNA must be ≤ 2.5 × 10³ copies\u002FmL (or ≤ 500 IU\u002FmL, or below LLoQ); HBsAg(+) subjects must receive anti-HBV prophylaxis throughout study treatment.\n   * HCV-seropositive allowed only if HCV RNA negative (or below LLoQ).\n10. History or current evidence of leptomeningeal metastases. Active brain metastases: untreated and\u002For symptomatic, or requiring corticosteroids or anticonvulsants. Subjects treated with surgery or radiotherapy may enter if imaging ≥ 4 weeks shows stable CNS disease, symptoms have resolved, no corticosteroids for ≥ 2 weeks, and acute toxicities have recovered.\n11. Other severe uncontrolled disorders (e.g., frequent seizures, hepatic failure).\n12. Other malignancies within 5 years, except adequately treated basal-cell carcinoma of skin or cervical carcinoma in situ.\n13. Participation in another clinical drug trial within 4 weeks or less than 5 half-lives of the previous investigational agent, whichever is longer.\n14. Any social or medical condition that, in the investigator's opinion, could interfere with informed consent, study participation, or interpretation of results.\n15. Patients deemed by the investigator to be unsuitable for enrollment.","75 Years",{"count":214,"type":23},30,[216],"PHASE2","This is a single-center, single-arm study designed to evaluate the efficacy and safety of second-line treatment in patients with advanced colorectal cancer (those who have progressed on or are intolerant to first-line oxaliplatin-based regimens with or without targeted therapy) receiving Levofolinic Acid + 5-FU continuous infusion combined with irinotecan hydrochloride liposome ± cetuximab\u002Fbevacizumab. Approximately 30 patients will be enrolled.",[219],"Metastatic Colorectal Cancer",{"date":114,"type":32},{"date":222,"type":32},"2025-11-01",{"date":224,"type":23},"2029-05-31",{"name":38,"class":39},{"id":227,"slug":228,"hasResults":12,"nctId":229,"briefTitle":230,"officialTitle":231,"acronym":4,"eligibilityCriteria":232,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":233,"targetDuration":4,"studyType":125,"phases":234,"briefSummary":235,"conditions":236,"keywords":239,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":242,"lastUpdatePostDateStruct":243,"startDateStruct":245,"completionDateStruct":247,"leadSponsor":249,"locationsCount":40},"100632084","phase-2-il-15-armored-car-t-therapy-in-relapsed-or-refractory-multiple-myeloma-and-plasma-cell-leukemia-100632084","NCT07509086","IL-15-Armored CAR-T Therapy in Relapsed or Refractory Multiple Myeloma and Plasma Cell Leukemia","A Clinical Study Evaluating the Safety and Efficacy of IL-15-armored Novel CAR-T Cell Therapy in Patients With Relapsed\u002FRefractory Multiple Myeloma and Plasma Cell Leukemia","Inclusion Criteria:\n\n1. Able and willing to provide written informed consent and comply with the scheduled visits, study treatment, laboratory assessments, and other study procedures.\n2. Clinically diagnosed relapsed or refractory multiple myeloma or plasma cell leukemia (PCL). Patients with persistent minimal residual disease (MRD) positivity or conversion from MRD-negative to MRD-positive status following induction and consolidation therapy are also eligible for enrollment.\n3. Age 18 to 80 years, inclusive.\n4. Eastern Cooperative Oncology Group (ECOG) performance status of 0-3.\n5. Estimated life expectancy \\> 3 months from the date of signing the informed consent form.\n6. Hemoglobin ≥ 60 g\u002FL (transfusion permitted).\n7. Adequate organ function as defined below:\n\n   * Creatinine clearance (CrCl) ≥ 40 mL\u002Fmin, calculated using the Cockcroft-Gault formula;\n   * Left ventricular ejection fraction (LVEF) ≥ 50%;\n   * Oxygen saturation \\> 90% on room air;\n   * Total bilirubin ≤ 1.5 × upper limit of normal (ULN); alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤ 2.5 × ULN.\n8. Participants of childbearing potential must agree to use effective contraception prior to study enrollment and for at least 6 months after completion of study treatment. Participants who become pregnant or suspect pregnancy must notify the investigator immediately.\n\nExclusion Criteria:\n\n1. History within 1 year prior to signing the informed consent form of any of the following:\n\n   * New York Heart Association (NYHA) Class III or IV heart failure;\n   * Myocardial infarction;\n   * Cardiac angioplasty or stent placement;\n   * Unstable angina;\n   * Other clinically significant symptomatic cardiac disease;\n2. Active graft-versus-host disease (GVHD) or requirement for systemic immunosuppressive therapy.\n3. History of other malignancies within 5 years prior to screening, except for adequately treated carcinoma in situ of the cervix, basal cell carcinoma or squamous cell carcinoma of the skin, localized prostate cancer after radical surgery, or ductal carcinoma in situ of the breast after curative surgery.\n4. Active infection requiring systemic therapy or uncontrolled infection within 7 days prior to screening (excluding mild genitourinary or upper respiratory tract infections).\n5. Evidence of active viral or infectious disease as follows:\n\n   * Positive hepatitis B surface antigen (HBsAg) or hepatitis B core antibody (HBcAb) with peripheral blood hepatitis B virus (HBV) DNA above the lower limit of detection;\n   * Positive hepatitis C virus (HCV) antibody with detectable HCV RNA;\n   * Positive human immunodeficiency virus (HIV) antibody;\n   * Positive Treponema pallidum particle agglutination assay (TPPA).\n6. Participation in another clinical trial within 4 weeks prior to signing the informed consent form, or if the time from the last dose of an investigational drug to informed consent is less than 5 half-lives of that drug (whichever is longer).\n7. History of severe allergic reactions to biologic products.\n8. Any unstable systemic disease, as judged by the investigator, including but not limited to severe hepatic, renal, or metabolic disorders requiring medical treatment.\n9. Pregnant or breastfeeding women; women planning to become pregnant within 2 years after cell infusion; or male participants whose partners plan to become pregnant within 2 years after cell infusion.\n10. Any condition that, in the opinion of the investigator, may increase the participant's risk or interfere with study participation or interpretation of study results.",{"count":7,"type":23},[216],"This is an open-label, single-arm, Phase 2 study to evaluate the efficacy and safety of IL-15-armored chimeric antigen receptor T-cell (CAR-T) therapy in subjects with relapsed or refractory multiple myeloma and plasma cell leukemia.",[237,238],"Relapsed\u002FRefractory Multiple Myeloma","Plasma Cell Leukemia (PCL)",[237,240,241],"Plasma Cell Leukemia","IL-15-armored CAR-T","2026-03-28",{"date":244,"type":32},"2026-04-03",{"date":246,"type":32},"2025-12-29",{"date":248,"type":23},"2029-07-15",{"name":38,"class":39},{"id":251,"slug":252,"hasResults":12,"nctId":253,"briefTitle":254,"officialTitle":254,"acronym":255,"eligibilityCriteria":256,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":257,"targetDuration":4,"studyType":125,"phases":259,"briefSummary":261,"conditions":262,"keywords":264,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":270,"lastUpdatePostDateStruct":271,"startDateStruct":273,"completionDateStruct":275,"leadSponsor":277,"locationsCount":40},"100631806","phase-2-efficacy-and-safety-comparison-of-short-course-radiotherapy-followed-by-capeox-chemotherapy-plus-toripalimab-with-or-without-concurrent-surufatinib-in-neoadjuvant-therapy-for-mid-to-low-localized-rectal-cancer-of-high-risk-criteria-100631806","NCT07505472","Efficacy and Safety Comparison of Short-course Radiotherapy Followed by CapeOX Chemotherapy Plus Toripalimab With or Without Concurrent Surufatinib in Neoadjuvant Therapy for Mid-to-low Localized Rectal Cancer of High-risk Criteria","STARS-RC10","Inclusion Criteria:\n\n* 1\\. Patients and their families are able to understand and willing to participate in this clinical study and sign the informed consent form; 2. Age: 18\\~75 years old, male or female; 3. Pathologically confirmed rectal tubular adenocarcinoma; Differentiation into Grade 1-3, i.e., high, intermediate, and low-grade adenocarcinoma; pMMR\u002FMSS phenotype; 4. Medium and low rectal cancer with the lower edge of the tumor located within 10cm from the anal verge; 5. Inclusion of treatment-naïve risk factors: cT4\u002FcN2\u002FmrMRF+\u002FEMVI+ or lateral lymph node involvement.\n\n  6\\. No distant metastases; 7. ECOG score 0-1; 8. Hepatitis B surface antigen (HBsAg) (-) and hepatitis B core antibody (HBcAb) (-). If HBsAg (+) or HBcAb (+), hepatitis B virus deoxyribonucleic acid (HBV-DNA) must \\\u003C 1000 copies\u002FmL or 200 IU\u002FmL for enrollment; 9. HCV antibody (-); 10. Negative serum or urine pregnancy test for females of childbearing age; 11. Females of childbearing potential or males with potential reproductive partners should agree to use adequate contraception (such as intrauterine devices, birth control pills, or condoms) for the duration of the study and for 120 days after the end of the study; 12. No history of pelvic radiotherapy; 13. No history of surgery or chemotherapy for rectal cancer; 14. Not accompanied by systemic infections requiring antibiotic treatment; 15. Heart, lung, liver, and kidney function can tolerate surgery;\n\nExclusion Criteria:\n\n* 1\\. Recurrent rectal cancer; 2. ECOG score of 2 points or above; 3. Occurrence of cardiovascular and cerebrovascular diseases within 6 months prior to the first dose: cerebrovascular accident\u002Fstroke, myocardial infarction, unstable angina, poorly controlled arrhythmias (including QTc interval ≥ 450 ms for males and 470 ms for females≥ (QTc interval is calculated by Fridericia's formula); 4. Presence of NYHA standard grade III.\\~IV. cardiac insufficiency or cardiac color ultrasound examination: LVEF (left ventricular ejection fraction) \\\u003C 50%; 5. Presence of hypertension (systolic blood pressure ≥ 140mmHg or diastolic blood pressure ≥90mmHg) that cannot be controlled by antihypertensive drugs; 6. Urine routine showed that urine protein was ≥++, and 24-hour urine protein was \\> 1.0g; 7. History of immunodeficiency, including human immunodeficiency virus (HIV) infection; Other acquired, congenital immunodeficiency diseases; History of organ or bone marrow transplantation; 8. Treatment with a live vaccine within 28 days prior to the first dose, except inactivated viral vaccines for seasonal influenza; 9. Previous and current presence of known active or suspected autoimmune disease (except for patients with hypothyroidism controlled by hormone replacement therapy and type I diabetes mellitus who only require control with insulin replacement therapy); 10. Have active tuberculosis; 11. Patients with previous and current interstitial pneumonia, pneumoconiosis, radiation pneumonitis, drug-related pneumonia, severe impairment of lung function, etc., which may interfere with the detection and management of suspected drug-related pulmonary toxicity; 12. Previous treatment with other small molecule anti-angiogenic targeted drugs or antibody\u002Fdrug therapy against immune checkpoints, such as PD-1 inhibitors, PD-L1, CTLA4, etc.; 13. Known history of severe allergy to PD-1 monoclonal antibody active ingredient, TKI inhibitor related components, or any investigational drug excipient; 14. Patients with organ bleeding or bleeding tendency, except for rectal primary tumor bleeding (the investigator needs to assess the bleeding risk); 15. Those who have suffered from malignant tumors in the past; 16. Received other types of anti-tumor or experimental therapy; 17. Pregnant or lactating females; 18. Patients with central nervous system diseases or abnormal mental status, which may affect the patient's participation in this study; 19. Patients with other severe, acute and chronic diseases that may increase the risk of participating in the study and study medication, and are judged by the investigator to be unsuitable for participating in the clinical study;",{"count":258,"type":23},212,[216,260],"PHASE3","Why is this study conducted? The purpose of this study is to improve the treatment efficacy, particularly the pathological complete response rate, in patients with high-risk\u002Fextremely high-risk locally advanced rectal cancer (LARC). In recent years, with the combination of neoadjuvant chemoradiotherapy and immunotherapy, some progress has been made in the treatment of rectal cancer, but there are still problems of regional recurrence and distant metastasis. Therefore, developing new treatment strategies for these patients is particularly important.\n\nThe treatment of rectal cancer usually involves surgery, radiation therapy, and chemotherapy. The current treatment methods have gradually shifted towards neoadjuvant chemoradiotherapy combined with immunotherapy, and have shown good potential in some clinical trials. These studies suggest that combining short-range radiotherapy, anti angiogenic drugs, and immune checkpoint inhibitors may play an important role in improving patient prognosis and enhancing tumor response rates. However, the efficacy and safety of these plans in high-risk patients still need further validation.\n\nIn this context, the aim of our study is to compare the efficacy and safety of neoadjuvant short-course radiotherapy followed by four cycles of CapeOX chemotherapy combined with toripalimab, with or without concurrent surufatinib, in patients with mid-to-low locally advanced rectal cancer with high-risk factors identified by MRI (including any one or more of the following: cT4, cN2, EMVI+, MRF\u002FCRM+, or lateral lymph node metastas. This study aims to promote treatment optimization for LARC patients and provide new ideas for future treatments.\n\nWhy are you invited to participate in this study? We would like to invite you to participate in this study as you have been diagnosed with high-risk or extremely high-risk locally advanced rectal cancer, which meets the inclusion criteria of this study. Specifically, you need to meet the conditions for pathological diagnosis, have a suitable tumor location, and not have serious comorbidities or other excluded diseases (such as recurrent rectal cancer, cardiac dysfunction, etc.). The final selection will be determined by the research doctor based on your actual situation.\n\nWhat do you need to do to participate in this study? Participating in this study will require you to follow a series of steps. You need to undergo regular medical examinations and evaluations, including blood tests, imaging examinations, and anorectal function assessments. During the research period, you may also need to fill out a questionnaire and provide some biological samples (such as blood samples), which will be used for the analysis of drug efficacy. The frequency and specific content of each follow-up will be informed by the research team to ensure your participation throughout the entire treatment process. I hope you can cooperate with these research steps to help us better understand the effectiveness of this treatment plan.\n\nWhat are the risks of participating in this study?\n\nThis study involves the use of neoadjuvant short course radiotherapy, PD-1 monoclonal antibody (Terizumab), and anti angiogenic therapy (Sofantinib). Participants may face the following risks:\n\nRisk of neoadjuvant short course radiotherapy: Participants may experience severe side effects (≥ grade 3), including but not limited to severe diarrhea, third degree neutropenia, and third degree radiation dermatitis. These side effects may seriously affect the quality of life of patients.\n\nRisk of PD-1 monoclonal antibody: Terriptylimab may cause immune related adverse reactions (irAEs), which can involve any organ. The commonly known irAEs include skin toxicity (such as papules and itching, with an incidence of 30% to 40%), diarrhea and\u002For colitis (8% to 19%), fatigue (16% to 24%), immune related hepatitis (5%), hypothyroidism (4% to 10%), and hyperthyroidism (4%). Overall, nearly two-thirds (about 2\u002F3) of patients receiving immune checkpoint inhibitor therapy will experience varying degrees of irAEs, and the incidence of serious adverse events cannot be ignored.\n\nRisk of anti angiogenic therapy: The use of sorafenib may lead to adverse reactions related to its anti angiogenic and immunomodulatory effects. Known common adverse reactions include proteinuria, hypertension, bleeding, liver dysfunction, diarrhea, etc., with an incidence rate of over 20%. Among serious adverse events (≥ grade 3), hypertension (29.7%), proteinuria (14.5%), liver dysfunction (12.8%), and bleeding (4.5%) are the most common. In rare cases, treatment-related deaths may occur due to gastrointestinal bleeding, cerebral hemorrhage, etc.\n\nHandling of research related injuries? This study is an intervention study that does not add any additional risks beyond routine clinical diagnosis and treatment. If you suffer harm due to participating in the study, compensation or liability will be determined in accordance with relevant laws and regulations.",[263],"Rectal Cancer",[265,266,267,268,269],"locally advanced rectal cancar","neoadjuvant treatment","short course radiotherapy","Toripalimab","Surufatinib","2026-03-26",{"date":272,"type":32},"2026-04-01",{"date":274,"type":32},"2026-02-23",{"date":276,"type":23},"2029-12-31",{"name":38,"class":39},{"id":279,"slug":280,"hasResults":12,"nctId":281,"briefTitle":282,"officialTitle":282,"acronym":4,"eligibilityCriteria":283,"healthyVolunteers":12,"sex":149,"minAge":284,"maxAge":285,"enrollmentInfo":286,"targetDuration":4,"studyType":125,"phases":288,"briefSummary":290,"conditions":291,"keywords":293,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":297,"startDateStruct":299,"completionDateStruct":301,"leadSponsor":303,"locationsCount":40},"100630911","phase-4-single-arm-prospective-study-of-the-efficacy-and-safety-of-paitelingantibacterial-liquid-in-the-treatment-of-persistent-cervical-hr-hpv-infection-100630911","NCT07493824","Single-arm, Prospective Study of the Efficacy and Safety of Paiteling®Antibacterial Liquid in the Treatment of Persistent Cervical HR-HPV Infection","Inclusion Criteria:\n\n* 1 、 Age 25 to 65 years (inclusive), persistent cervical HR-HPV infection (HR-HPV persistent infection refers to infection with the same high-risk HPV subtypes for ≥2 years (this can be from different testing companies; for multiple infections, only one subtyping of HPV persistence is required)); if the cervical biopsy shows chronic cervicitis or low-grade cervical intraepithelial neoplasia; 2. Sexual history; 3. No relevant anti-HPV virus treatment (vaginal or systemic) in the 3 months prior to visit; 4. No pregnancy plan within 6 months of visit 5、 Voluntary signing of informed consent.\n\nExclusion Criteria:\n\n* 1、 Cervical biopsy results of TCT or HSIL; 2 、 Cervical HR-HPV infection subtypes changed or reversed to negative; 3. Pregnant or lactating women; 4. Acute inflammation of the genital tract; 5Recent immunodeficiency (chemoradiotherapy, AIDS, SLE); 6. Patients with severe diseases such as diabetes, cardiovascular disease, brain, liver, kidney and hematopoietic system, and mental illness; 7. Those with a history of drug allergy and allergic constitution; 8 Patients who have participated in other clinical trials in the last three months; 9. Suspected or confirmed history of alcohol or drug abuse, or other lesions or conditions that reduce the possibility of enrollment or complicate enrollment, such as frequent changes in work environment and unstable living environment that are likely to cause loss of follow-up, according to the investigator's judgment.","26 Years","65 Years",{"count":287,"type":23},115,[289],"PHASE4","The effectiveness of Patellin ® antibacterial solution in treating persistent cervical HR-HPV infection",[292],"Persistent HR-HPV Infection of the Cervix",[294,295],"Patling ® Antibacterial Liquid","Treatment for persistent HPV infection","2026-03-21",{"date":298,"type":32},"2026-03-25",{"date":300,"type":32},"2025-07-24",{"date":302,"type":23},"2028-05-31",{"name":38,"class":39},{"id":305,"slug":306,"hasResults":12,"nctId":307,"briefTitle":308,"officialTitle":308,"acronym":4,"eligibilityCriteria":309,"healthyVolunteers":12,"sex":149,"minAge":19,"maxAge":212,"enrollmentInfo":310,"targetDuration":4,"studyType":125,"phases":312,"briefSummary":313,"conditions":314,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":316,"startDateStruct":318,"completionDateStruct":319,"leadSponsor":321,"locationsCount":40},"100631032","single-arm-prospective-clinical-trial-of-efficacy-and-safety-of-daphnetin-capsules-combined-with-tc-regimen-for-targeted-maintenance-therapy-after-initial-treatment-of-stage-iii-iv-epithelial-ovarian-cancer-ror1-100631032","NCT07495397","Single-arm, Prospective Clinical Trial of Efficacy and Safety of Daphnetin Capsules Combined With TC Regimen for Targeted Maintenance Therapy After Initial Treatment of Stage III-IV Epithelial Ovarian Cancer (RO\u002FR1)","Inclusion Criteria:\n\n* Inclusion Criteria:\n\n  1. Patients with stage III-IV treatment-naïve ovarian cancer aged 18 to 75 years (including cut-off values) who have completed satisfactory tumor cytoreductive surgery (R0+R1);\n  2. Voluntarily sign the informed consent form;\n  3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1;\n  4. Expected survival ≥ 12 weeks as assessed by the investigator;\n  5. Adequate organ and bone marrow reserve.\n  6. Willing to provide previous archival or fresh tumor tissue samples (if there is no previous archived tumor tissue, and the investigator assesses that the patient has a high risk of re-retrieving the primary or metastatic part of the tumor tissue specimen is exempted);\n  7. Able to understand the requirements of the trial, willing and able to comply with the trial and follow-up procedures.\n\nExclusion Criteria:\n\n* Exclusion Criteria: Those who meet any of the following conditions cannot be admitted to this trial:\n\n  1. With bleeding tendency PT≥15s or platelet count \\\u003C90×109\u002FL or plasma fibrinogen ≤ 1.6g\u002FL;\n  2. with pulmonary artery embolism, inferior vena cava thrombosis;\n  3. Primary central nervous system tumors or symptomatic central nervous system metastases, meningeal metastases or previous history of epilepsy. Patients with asymptomatic clinical control or central nervous system metastases that are symptomatic but judged stable by the investigator can be included, but the following conditions must be met at the same time: a. 4 weeks from stable clinical symptoms before the first dose≥ b. No evidence of progression of central nervous system disease with enhanced cranial MRI within 4 weeks prior to the first dose; c. Antiepileptic drugs, prednisone dosage ≤10mg\u002Fday or equivalent dose of hormones have been discontinued ≥ 2 weeks before the first dose;\n  4. Other active malignancy within 5 years prior to the first dose. Except for locally cured tumors (e.g., basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer or carcinoma in situ of the breast, etc.);\n  5. The following cardiovascular disease occurred within 6 months prior to the first dose: symptomatic heart failure with New York Heart Association Class (NYHA) of grade 2 or higher, left ventricular ejection fraction (LVEF) \\\u003C50%, unstable arrhythmia or unstable angina, myocardial infarction requiring treatment, pulmonary embolism, uncontrolled hypertension (This protocol is defined as post-treatment systolic blood pressure \\>160 mmHg and\u002For diastolic blood pressure \\>100 mmHg despite optimal antihypertensive therapy , and the investigator assesses that it is clinically significant);\n  6. Have any other disease, physical examination or laboratory test results that make the use of the study drug unsuitable according to the investigator's judgment;\n  7. Patients with chronic oral vitamin K disease are combined\n  8. Subjects with untreated or under treatment for tuberculosis, including but not limited to pulmonary tuberculosis; Those who have received standardized anti-tuberculosis treatment and have been confirmed to be cured by the investigator can be included;\n  9. Serious infection within 4 weeks or active infection within 2 weeks before the first dose;\n  10. Those with the following diseases: human immunodeficiency virus (HIV) infection; Active hepatitis B virus infection \\[positive hepatitis B surface antigen (HBsAg) and hepatitis B virus deoxyribonucleic acid (HBV-DNA) test \\>200 IU\u002Fml or 103 copies\u002Fml\\]; Hepatitis C virus infected \\[positive HCV antibody and viral ribonucleic acid (HCV-RNA) test results\\]; Treponema pallidum antibody positive and RPR positive;\n  11. Known hypersensitivity or delayed allergic reaction to any component of the study drug;\n  12. Known history of psychotropic, drug abuse, alcohol or drug abuse that affects the test results; Estimated insufficient compliance of patients to participate in this clinical study or having other factors that are considered unsuitable for participation in this study in the opinion of the investigator.",{"count":311,"type":23},98,[127],"Imaging evaluation was performed every 3 months (± 7 days) from enrollment, and real-time examination was performed if new lesions were suspected.\n\nThe study was divided into two parts:\n\nPart 1: Rexiacin capsules assist in the treatment phase of the TC regimen. Part 2: Rexiacin capsule combined with targeted drug maintenance therapy after the end of chemotherapy.\n\nThe overall research cycle is roughly divided into screening period, treatment period, and follow-up period:\n\nScreening period: -7d\\~0d, that is, after the signing of the informed consent form, the screening assessment must be completed within 7 days; Treatment period: 1 dosing cycle every 3 weeks; During chemotherapy, blood routine, liver and kidney function tests were performed every week, tumor marker monitoring and safety evaluation were performed every cycle, and imaging evaluations were performed every 3 months (± 7 days) to evaluate the efficacy. After the end of chemotherapy, the maintenance treatment period and follow-up stage will be conducted, and biochemical tests such as tumor markers, blood routine, liver and kidney function will be performed every 3 months (± 7 days), and imaging evaluation will be performed to evaluate the efficacy, and the patient's self-evaluation results will be evaluated (FOSI, EQ-5D-5L). Peripheral blood immune indicators: Peripheral blood TBNK+Treg lymphocyte subset typing and activated lymphocyte cytokines were performed every 6 months (± 7 days) to monitor the patient's immune status. Medication is administered until an event that meets the criteria for treatment termination occurs or the clinical trial is closed.\n\nClinical tumor imaging evaluation was completed (the evaluation method was consistent before and after, enhanced CT or enhanced MRI was preferred). Investigational drug treatment should be continued until the occurrence of disease progression, or withdrawal due to intolerable toxicity, or receipt of new anti-tumor therapy, or withdrawal of informed consent and voluntary withdrawal for other reasons, or study termination, whichever occurs first. The termination time of the study is the last subject who has received the study drug for 1 year or all subjects are out of the group, whichever is achieved first.\n\nFollow-up period: If the investigator decides to end the subject's treatment with the study drug, then the treatment period will be considered the end of (End of Therapy, EOT). All subjects, including those who discontinue treatment for any reason (except for loss to follow-up, death, withdrawal of informed consent), will have an EOT visit scheduled within 7 days after the investigator decides to end the subject's treatment with study drug. The EOT visit should include vital signs, physical examination, laboratory tests, and clinical tumor imaging evaluation (first enhanced CT or enhanced MRI).\n\nSafety follow-up: Subjects are required to have a safety visit 30 days (+7 days) after the last dose. If the subject plans to receive a new anti-tumor treatment within 30 days after the last dose, a safety follow-up will be conducted before receiving the new anti-tumor therapy. Safety visits are required at the study center and should be performed to assess for AEs, concomitant medications, and concomitant treatments. Until adverse reactions related to the study drug disappear, or drop to Grade ≤1, or return to baseline levels, or stable or acceptable levels assessed by the investigator.\n\nSurvival follow-up: After the safety follow-up, subjects will be followed up for survival once every 3 months (± 7 days), and will be followed up by telephone until death, loss to follow-up, withdrawal of informed consent, or termination of the study.",[315],"Epithelial Ovarian Cancer",{"date":317,"type":32},"2026-03-27",{"date":222,"type":32},{"date":320,"type":23},"2028-06-01",{"name":38,"class":39},{"id":323,"slug":324,"hasResults":12,"nctId":325,"briefTitle":326,"officialTitle":326,"acronym":4,"eligibilityCriteria":327,"healthyVolunteers":12,"sex":149,"minAge":19,"maxAge":4,"enrollmentInfo":328,"targetDuration":4,"studyType":125,"phases":330,"briefSummary":331,"conditions":332,"keywords":335,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":338,"startDateStruct":339,"completionDateStruct":341,"leadSponsor":343,"locationsCount":40},"100631031","efficacy-and-safety-of-capsulex-combined-with-cisplatin-in-platinum-resistant-recurrent-ovarian-cancer-a-single-arm-prospective-clinical-study-100631031","NCT07495384","Efficacy and Safety of CapsuleX Combined With Cisplatin in Platinum-Resistant Recurrent Ovarian Cancer: A Single-Arm Prospective Clinical Study","Inclusion criteria\n\n1. The subject can understand the informed consent, voluntarily participate and sign the informed consent;\n2. The subject is at least 18 years old on the day of signing the informed consent;\n3. Subjects with histologically confirmed epithelial ovarian cancer, fallopian tube cancer or primary peritoneal cancer;\n4. Platinum resistance is defined as: a. For subjects who have only received first-line platinum-based therapy, they must have received at least four cycles of platinum-based therapy and achieved disease response (CR or PR), with disease progression occurring between\\>3 months and ≤6 months after the last platinum-based treatment; b. For subjects who have received more than two lines of platinum-based therapy, disease progression must occur within \\\u003C6 months after the last platinum-based treatment (at least two cycles).\n5. The subject must have had progression or intolerance during or after the most recent treatment;\n6. Previous 2-3 line systemic antitumor therapy, with progression within \\\u003C6 months after the last platinum treatment and ≥3 months Note: a. New adjuvant and\u002For adjuvant therapy combined as line 1 treatment; b. Maintenance therapy (including monotherapy, targeted therapy, immunotherapy, and hormone therapy in the initial combination regimen) is considered part of the initial treatment (i.e., not counted separately); c. Lack of evidence of disease progression due to drug switching caused by toxicity is not considered a single treatment line (i.e., not counted separately); d. Insufficiently evaluated treatments without efficacy assessment (≤2 treatment cycles) are not considered a single treatment line (i.e., not counted separately); e. Endocrine therapy and targeted therapy are counted as separate lines unless used as maintenance therapy;\n7. According to RECIST 1.1, the baseline should have at least 1 measurable lesion. Measurable lesions should not have been previously received Local treatment (such as radiotherapy), or evidence of disease progression after local treatment;\n8. Expected survival time is greater than or equal to 6 months;\n9. ECOG score 0 or 1;\n10. Sufficient organ\u002Fmarrow function within 7 days prior to randomization, asdefined below;\n11. Willing to provide archived or fresh tumor tissue samples (if no archived tumor tissue is available and the investigator assesses that it would be risky for the subject to retrieve primary or metastatic tumor tissue samples);\n12. Able to understand the test requirements and willing and able to comply with the test and follow-up procedures.\n\nExclusion criteria\n\n1. Primary platinum-refractory is defined as disease that has not been relieved (CR) during first-line platinum-containing chemotherapy or within 3 months after the last dose Or PR) or imaging progression;\n2. History of active central nervous system metastasis, leptomeningeal metastasis or carcinomatous meningitis with stable evaluation by the investigator Excluding brain parenchyma metastases, stability is defined by the following criteria: no related symptoms and at least one recent imaging showing a stable state; or stable for more than 1 month without symptoms after treatment, and no need to use glucocorticoids or anticonvulsants for at least 2 weeks;\n3. Received any investigational drug within 28 days prior to randomization;\n4. Five half-lives (the shorter time) within 28 days prior to randomization of other antitumor therapy or antitumor drugs Equivalent but at least 14 days); Received Chinese herbal medicine with a clear anti-tumor indication within 14 days prior to randomization;\n5. Received local palliative treatment within 14 days prior to randomization;\n6. Had major surgery (such as abdominal or thoracic surgery; not including diagnostic surgery) within 28 days prior to randomization Small operations such as puncture or infusion device implantation or biliary stent implantation), or major surgery is expected to be required during the study treat;\n7. There are obvious clinical manifestations of gastrointestinal abnormalities, including but not limited to: intestinal obstruction existed or existed within 3 months before administration Symptoms and signs of intestinal obstruction, but screening can be performed if surgery has been performed and the obstruction is completely relieved (if previously received Patients who have undergone gastrointestinal stent implantation and whose stents remain in place at the screening stage are not eligible for enrollment); within 3 months before dosing, there has been a gastrointestinal perforation, gastrostomy, or intra-abdominal abscess; within 3 months before dosing, there has been CTCAE grade ≥3 gastrointestinal bleeding, or within 1 month before randomization, there has been gastrointestinal bleeding (including melena, hematochezia, etc., if confirmed as hemorrhoidal bleeding or only positive occult blood in stool, they can be enrolled);\n8. Uncontrolled and recurrent (recurrent within 2 weeks of intervention) moderate to large pleural effusions such as the chest Subjects with water, pericardial effusion, ascites and cachexia;\n9. Other malignant tumors were combined within the previous 5 years, excluding curable squamous cell carcinoma of skin, basal cell carcinoma and non-basal infiltration Bladder cancer with lubrication, in situ prostate\u002Fcervical\u002Fbreast cancer;\n10. Past or current interstitial pneumonia\u002Fpulmonary disease requiring systemic glucocorticoid therapy, or imaging during screening The examination could not rule out suspected interstitial pneumonia\u002Fpulmonary disease;\n11. The presence of uncontrolled comorbidities, including but not limited to:\n\n    * Active HBV or HCV infection. HBsAg (+), HBV-DNA \\\u003C2500 copies\u002FmL or 500 Enrollment is allowed at IU\u002FmL; enrollment is allowed if HCV-Ab (+) and HCV-RNA test is negative;\n    * HIV infection;\n    * Known active tuberculosis;\n    * Active syphilis;\n    * There is an active or uncontrolled infection within 2 weeks prior to the randomization, and systemic antimicrobial therapy is required;\n    * Uncontrolled hypertension (systolic blood pressure ≥180mmHg, diastolic blood pressure\\> 100 mmHg) and symptomatic heart failure Full (NYHA II-IV), refractory hypokalemia, long QT syndrome, moderate to severe pulmonary hypertension;\n    * Severe arrhythmias of important medical significance, including but not limited to ventricular tachycardia, ventricular fibrillation, and apex torsion A history of transition tachycardia, complete left or right bundle branch block, second or third degree cardiac conduction block;\n    * Unstable angina or myocardial infarction within 6 months;\n    * New diagnosis of a treatable thromboembolic event within 6 months (control of stable lower extremity deep vein thrombosis or infusion Thrombosis subjects such as liquid ports are allowed to be included)\n12. The toxicity of previous anti-tumor therapy has not been restored to CTCAE≤1 grade (NCI-CTCAE v5.0); Note: Participants with stable grade CTCAE 2 toxicity related to prior anti-tumor therapy can be enrolled (defined as stable toxicity severity within 3 months before dosing, with no CTCAE grade greater than 2), such as neurotoxicity, hair loss, skin pigmentation, fatigue caused by chemotherapy, and endocrine toxicity from prior immunotherapy (e.g., thyroid dysfunction, diabetes, hyperglycemia, adrenal insufficiency);\n13. Previous history of allogeneic bone marrow or organ transplantation;\n14. History of previous allergic reactions to antibody drugs and hypersensitivity reactions;\n15. Other researchers believe that conditions that may affect the safety or compliance of treatment with the study drug, including but not limited to mental illness Class diseases, alcoholism or drug abuse, etc.",{"count":329,"type":23},40,[127],"This trial was designed as a single-arm, open-label, prospective clinical trial to evaluate the efficacy (ORR) and safety (AE incidence) of CapsuleX in combination with cisplatin for platinum-resistant recurrent ovarian cancer (PROC).",[333,334],"Recurrent Ovarian Cancer","Platinum Resistance",[336,337],"CapsuleX","cisplatin",{"date":317,"type":32},{"date":340,"type":32},"2025-01-17",{"date":342,"type":23},"2029-11-01",{"name":38,"class":39},{"id":345,"slug":346,"hasResults":12,"nctId":347,"briefTitle":348,"officialTitle":349,"acronym":350,"eligibilityCriteria":351,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":212,"enrollmentInfo":352,"targetDuration":4,"studyType":125,"phases":354,"briefSummary":355,"conditions":356,"keywords":361,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":296,"lastUpdatePostDateStruct":366,"startDateStruct":367,"completionDateStruct":369,"leadSponsor":371,"locationsCount":372},"100621354","the-impact-of-two-stage-turnbull-cutait-pull-through-coloanal-anastomosis-on-stoma-free-survival-in-low-rectal-anal-preserving-surgery-100621354","NCT07369531","The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-preserving Surgery","The Impact of Two-Stage Turnbull-Cutait Pull-Through Coloanal Anastomosis on Stoma-free Survival in Low Rectal Anal-preserving Surgery: A Multicenter Randomized Controlled Trial (FIAS)","FIAS","Inclusion Criteria:\n\n1. Patients with rectal cancer aged 18-75 years confirmed by pathological biopsy as adenocarcinoma;\n2. Preoperative abdominal contrast-enhanced CT and pulmonary CT (or PET-CT) showed no evidence of distant metastasis;\n3. Preoperative rectal MRI evaluation demonstrated that the tumor was located within 5cm below the anal margin, above the intermuscular groove between the internal and external anal sphincters (anal white line) by 1 cm, and without invasion of the external anal sphincter;\n4. For tumors located above the levator ani hiatus, MRI evaluation showed cT1-3, cN0-1, M0, MRF (-); for tumors located below the levator ani hiatus, MRI evaluation showed cT1-2, cN0-1, M0, MRF (-). For patients who received neoadjuvant therapy, tumors above the levator ani hiatus were downstaged to ycT3NxM0 or below, and tumors below the levator ani hiatus were downstaged to ycT2NxM0 or below;\n5. Preoperative BMI \\\u003C 28 kg\u002Fm²\n6. Patients underwent radical laparoscopic\u002Frobot-assisted total mesorectal excision (TME) or transanal total mesorectal excision (TaTME).\n\nExclusion Criteria:\n\n1. Patients diagnosed with concurrent primary malignant tumors in any other organ or multiple distant colorectal cancers;\n2. History of previous open surgery (non-minimally invasive procedures);\n3. Failure to undergo preoperative rectal MRI evaluation and chest\u002Fabdominal imaging assessment, resulting in incomplete clinical staging of the tumor;\n4. Pregnant patients or those with concurrent inflammatory bowel disease;\n5. Preoperative patients with complete intestinal obstruction or requiring emergency surgery;\n6. Preoperative anticipated multivisceral resection or intraoperative required combined organ resection is indicated.;\n7. Recent treatment for other malignancies;\n8. Low rectal cancer classified as type IV in the Bordeaux classification system;\n9. Intraoperatively confirmed distant metastatic disease\n10. Preoperative pathological types of signet ring cell carcinoma, mucinous adenocarcinoma, anaplastic carcinoma, or poorly differentiated carcinoma.\n\nWithdrawal Criteria\n\n1. Patients who refuse surgical intervention after randomization.\n2. Patients who undergo an abdominoperineal resection (APR) following randomization.\n3. Patients who request voluntary withdrawal from the trial at any time throughout the study period.",{"count":353,"type":23},520,[127],"The goal of this clinical trial is to explore the difference in 3-year stoma-free survival between the Turnbull-Cutait delayed coloanal anastomosis (TCA) surgery and the low anterior resection combined with protective stoma (LAR) surgery in patients with low rectal cancer, as well as the differences in anal function, surgical complications, and survival outcomes within 1 year after surgery. The main questions it aims to answer are:\n\n1. Is TCA surgery superior to LAR surgery in improving the 3-year stoma-free survival of patients with low rectal cancer?\n2. Are there differences in postoperative anal function (assessed by LARS score and Wexner score), quality of life (assessed by EORTC QLQ-CR29 questionnaire), surgical complications, pathological outcomes, and long-term survival (disease-free survival, time to recurrence, overall survival) between the two surgical methods? Researchers will compare the TCA group and the LAR group to see if TCA surgery can reduce the permanent stoma rate, improve postoperative anal function and quality of life, and ensure surgical safety and favorable tumor-related outcomes compared with LAR surgery.\n\nParticipants will:\n\n1. Be randomly assigned to either the TCA group or the LAR group in a 1:1 ratio.\n2. Receive the corresponding surgical intervention.\n3. Complete regular follow-ups at 1 month, 3 months, 6 months, 9 months, 12 months, 18 months, 24 months, 30 months, and 36 after the first surgery.\n4. Provide relevant clinical data (perioperative, pathological, follow-up) as required.",[263,357,358,359,360],"Surgical Anastomosis","Survival , Tumor","Anal Function","Stoma",[362,363,364,365],"Turnbull-Cutait anastomosis","Rectal neoplasms","Low anterior resection","Stoma-free survival",{"date":298,"type":32},{"date":368,"type":32},"2026-03-18",{"date":370,"type":23},"2031-12-31",{"name":38,"class":39},2,{"id":374,"slug":375,"hasResults":12,"nctId":376,"briefTitle":377,"officialTitle":378,"acronym":4,"eligibilityCriteria":379,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":380,"targetDuration":382,"studyType":24,"phases":4,"briefSummary":383,"conditions":384,"keywords":388,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":392,"startDateStruct":394,"completionDateStruct":396,"leadSponsor":398,"locationsCount":4},"100626802","enterocyte-injury-and-acute-gastrointestinal-dysfunction-in-critical-illness-100626802","NCT07440368","Enterocyte Injury and Acute Gastrointestinal Dysfunction in Critical Illness","Enterocyte Injury and Acute Gastrointestinal Dysfunction in Critical Illness: A Prospective Observational Study of Blood and Urinary Intestinal Fatty Acid-Binding Protein(Implications for Sepsis Heterogeneity）","Inclusion Criteria:\n\n* 1、 Age ≥18 years.\n* 2 、Admission to the ICU with an expected ICU stay ≥48 hours.\n* 3 、Availability of paired plasma and urine samples within 24 hours of ICU admission.\n* 4 、Feasible daily gastrointestinal function assessment to complete AGI grading (ESICM definition).\n\nExclusion Criteria:\n\n* 1、 Pre-existing inflammatory bowel disease.\n* 2 、Short bowel syndrome.\n* 3、 Chronic intestinal failure requiring long-term parenteral nutrition.\n* 4、 Pregnancy.\n* 5 、Refusal or withdrawal of informed consent.",{"count":381,"type":23},500,"28 Days","Acute gastrointestinal injury (AGI) is a common but not fully understood organ dysfunction in critically ill patients. Current AGI grading systems rely primarily on clinical presentation and feeding tolerance, which are inherently subjective and may not accurately reflect the underlying biological severity of intestinal damage.\n\nIntestinal fatty acid-binding protein (I-FABP) is a protein expressed almost exclusively in the cytoplasm of mature small intestinal epithelial cells. In cases of ischemia, inflammation, or mechanical injury, I-FABP is rapidly released into the bloodstream and subsequently excreted in the urine. These characteristics make I-FABP a highly specific biomarker for intestinal epithelial cell injury and intestinal ischemia.\n\nA prospective study combining paired blood and urine I-FABP measurements, standardized AGI assessment, and careful consideration of surgical status was conducted to elucidate the role of intestinal epithelial cell injury in acute gastrointestinal dysfunction.",[385,386,387],"Patients Admitted to the ICU","Expected Hospital Stay ≥48 Hours","Adult",[389,390,391],"Intestinal Fatty Acid-Binding Protein","Acute Gastrointestinal Dysfunction","Critical Illness",{"date":393,"type":32},"2026-02-27",{"date":395,"type":23},"2026-03-01",{"date":397,"type":23},"2026-12-01",{"name":38,"class":39},{"id":400,"slug":401,"hasResults":12,"nctId":402,"briefTitle":403,"officialTitle":404,"acronym":4,"eligibilityCriteria":405,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":406,"targetDuration":408,"studyType":24,"phases":4,"briefSummary":409,"conditions":410,"keywords":4,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":414,"startDateStruct":415,"completionDateStruct":417,"leadSponsor":419,"locationsCount":40},"100626773","study-of-risk-factors-and-prediction-of-blood-clots-after-lung-cancer-surgery-100626773","NCT07439991","Study of Risk Factors and Prediction of Blood Clots After Lung Cancer Surgery","Prospective Cohort Study on Risk Factors and Machine Learning-Based Prediction of Postoperative Venous Thromboembolism in Patients Undergoing Lung Cancer Surgery","Inclusion Criteria:\n\n1. Age ≥ 18 years\n2. Patients undergoing surgical resection for lung cancer\n3. Postoperative hospital stay ≥ 48 hours\n4. Availability of perioperative clinical, laboratory, and imaging data\n5. Willingness to provide informed consent and participate in 30-day follow-up\n\nExclusion Criteria:\n\n1. Pre-existing deep vein thrombosis (DVT) or pulmonary embolism (PE) before surgery\n2. Preoperative or ongoing anticoagulation therapy for ≥ 2 weeks\n3. Severe coagulation disorders or bleeding diseases\n4. Severe hepatic, renal, or hematologic dysfunction, or uncontrolled systemic infection\n5. Concurrent major organ surgery (e.g., cardiac, liver surgery)\n6. Pregnancy or lactation\n7. Incomplete postoperative follow-up data",{"count":407,"type":23},900,"30 Days","The goal of this observational study is to learn about the risk factors and prediction of postoperative venous thromboembolism (VTE) in patients undergoing lung cancer surgery. The main question it aims to answer is:\n\nWhich clinical, surgical, and laboratory factors are associated with the development of postoperative deep vein thrombosis (DVT) in lung cancer surgery patients, and can machine learning models accurately predict individual risk?\n\nParticipants undergoing lung cancer surgery will be prospectively followed for 30 days after surgery. Perioperative clinical data, laboratory results, and imaging findings will be collected to identify VTE risk factors and to develop a predictive model.",[411,412,413],"Lung Cancer (Diagnosis)","Deep Vein Thrombosis (DVT)","Venous Thromboembolism (VTE)",{"date":393,"type":32},{"date":416,"type":32},"2024-11-01",{"date":418,"type":23},"2029-11-30",{"name":38,"class":39},{"id":421,"slug":422,"hasResults":12,"nctId":423,"briefTitle":424,"officialTitle":424,"acronym":425,"eligibilityCriteria":426,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":427,"enrollmentInfo":428,"targetDuration":430,"studyType":24,"phases":4,"briefSummary":431,"conditions":432,"keywords":435,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":274,"lastUpdatePostDateStruct":440,"startDateStruct":441,"completionDateStruct":443,"leadSponsor":445,"locationsCount":40},"100626771","investigation-of-protein-heterogeneity-in-extracellular-vesicles-derived-from-different-human-blood-circulatory-regions-100626771","NCT07439965","Investigation of Protein Heterogeneity in Extracellular Vesicles Derived From Different Human Blood Circulatory Regions","DBCR-EV-p","Inclusion Criteria:\n\n* 1\\. Aged between 18 and 60 years, regardless of gender; 2. Diagnosed with intracranial aneurysm confirmed by MRA, CTA, or DSA; 3. Patients with aneurysmal subarachnoid hemorrhage must have CT imaging evidence of hemorrhage, and blood collection must occur within 3 days of symptom onset; 4. Scheduled to undergo neurointerventional surgery for intracranial aneurysm under general anesthesia, with the procedure starting between 8:00 AM and 12:00 PM; 5. Willing to comply with the study protocol and data collection procedures; 6. Able to understand and sign the informed consent form.\n\nExclusion Criteria:\n\n* 1\\. Patients with a pre-onset (in hemorrhagic cases) or preoperative (in non-hemorrhagic cases) Modified Rankin Scale (MRS) score ≥ 2; 2. Presence of other neurological disorders such as Parkinson's disease, Alzheimer's disease, cerebral infarction, brain tumors, epilepsy, etc.; 3. Presence of other systemic diseases such as diabetes, coronary artery disease, cancer, infections, hematological diseases, or severe metabolic disorders that may significantly affect the evaluation of blood EVs; 4. History of severe hepatic or renal dysfunction (ALT \\> 3 times the upper limit of normal; creatinine \\> 225 μmol\u002FL); 5. Patients who cannot tolerate anesthesia, anticoagulant therapy, or who have coagulation disorders; 6. History of severe allergic reactions to contrast agents; 7. Pregnant women; 8. Patients participating in other clinical trials who have not yet completed follow-up.","60 Years",{"count":429,"type":23},120,"120 Days","The goal of this observational study is to learn about the protein heterogeneity in extracellular vesicles (EVs) derived from different human blood circulatory regions of patients with ruptured or unruptured intracranial aneurysms. The main objectives are:\n\nReveal the proteomic heterogeneity of EVs in different blood circulatory regions of the human body。 Reveal the proteomic differences of EVs in cerebral feeding arteries and draining veins between patients with aneurysmal subarachnoid hemorrhage and those without hemorrhage.\n\nExplore EV-derived protein biomarkers that reflect the diagnosis and prognosis of subarachnoid hemorrhage",[433,434],"Subarachnoid Aneurysm Hemorrhage","Unruptured Intracranial Aneurysm",[436,437,438,439],"extracellular vesicles","blood","subarachnoid hemorrhage","intracranial aneurysm",{"date":393,"type":32},{"date":442,"type":32},"2025-07-29",{"date":444,"type":23},"2026-06",{"name":38,"class":39},{"id":447,"slug":448,"hasResults":12,"nctId":449,"briefTitle":450,"officialTitle":451,"acronym":452,"eligibilityCriteria":453,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":454,"targetDuration":382,"studyType":24,"phases":4,"briefSummary":455,"conditions":456,"keywords":458,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":462,"lastUpdatePostDateStruct":463,"startDateStruct":465,"completionDateStruct":467,"leadSponsor":469,"locationsCount":4},"100624786","association-between-dynamic-prealbumin-trajectories-and-prognosis-in-critically-ill-patients-100624786","NCT07414160","Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients","Association Between Dynamic Prealbumin Trajectories and Prognosis in Critically Ill Patients: A Prospective Observational Study","PAB-TRACK","Inclusion Criteria:\n\n1. age \\> 18 years,\n2. SOFA score ≥ 2\n3. at least three prealbumin data points within the previous 14 days.\n\nExclusion Criteria:\n\n1. patients with liver failure\n2. patients with kidney failure,\n3. hereditary amyloidosis and Alzheimer's disease\n4. long-term use of hormones or NSAIDs. -",{"count":381,"type":23},"Nutritional support therapy is a crucial part of ICU patient care, as both malnutrition and overnutrition can lead to adverse clinical outcomes. Meticulous monitoring of nutritional support is essential. Unfortunately, to date, there are no biomarkers available to assess the appropriateness of nutritional support in the ICU setting. However, mounting evidence suggests that phenotypic analysis of patients using nutritional biomarkers or risk screening scores for adaptation may enhance our ability to characterize patients in terms of prognosis and likelihood of treatment response.\n\nThis study aims to identify the trajectory patterns of prealbumin changes based on dynamic monitoring data of prealbumin during hospitalization of critically ill patients, and to analyze the Association between different trajectory groups and patient prognosis. In addition, this study will further analyze its Association with nutritional intake and nutritional indicators, thereby assessing the potential value of prealbumin change trajectories in terms of the adequacy and effectiveness of nutritional support for critically ill patients.",[457,391,387],"ICU",[459,460,461],"prealbumin","Critically Ill Patients","Prognosis","2026-02-10",{"date":464,"type":32},"2026-02-17",{"date":466,"type":23},"2026-03-15",{"date":468,"type":23},"2027-04-15",{"name":38,"class":39},{"id":471,"slug":472,"hasResults":12,"nctId":473,"briefTitle":474,"officialTitle":475,"acronym":476,"eligibilityCriteria":477,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":20,"enrollmentInfo":478,"targetDuration":4,"studyType":24,"phases":4,"briefSummary":480,"conditions":481,"keywords":483,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":489,"startDateStruct":491,"completionDateStruct":492,"leadSponsor":494,"locationsCount":4},"100616648","rapid-identification-of-infectious-pathogens-in-severe-pneumonia-guided-by-bronchoscopic-imaging-and-lung-ct-100616648","NCT07308340","Rapid Identification of Infectious Pathogens in Severe Pneumonia Guided by Bronchoscopic Imaging and Lung CT","Clinical Study on Rapid Identification of Infectious Pathogens in Severe Pneumonia Patients Based on Bronchoscopic Imaging and Lung CT Guidance","IMG-GUIDE-IP","Inclusion Criteria:\n\n* Patients admitted to the study institution between January 2024 and December 2025, with a clinical diagnosis of severe pneumonia (consistent with the diagnostic criteria of the Chinese Guidelines for the Diagnosis and Treatment of Community-Acquired Pneumonia.\n* Patients who underwent both standalone lung CT examination and bronchoscopic imaging examination during hospitalization; complete imaging reports and bronchoscopy operation records are available.\n* Patients who completed at least one type of microbial standard test (as defined in Primary Outcome Measure: e.g., pathogen culture, nucleic acid detection, GM test); complete test reports are available.\n* Medical Records: Complete electronic medical records are available, including demographic information (age, gender), clinical symptoms, treatment regimens, and prognosis data (length of hospital stay, in-hospital mortality).\n\nExclusion Criteria:\n\n* Imaging\u002FMicrobial Data Deficiency: Patients with incomplete imaging data (e.g., missing lung CT images, unrecorded bronchoscopic mucosal changes) or unavailable microbial gold standard test results.\n* Bronchoscopy Contraindications: Patients who underwent bronchoscopic imaging for non-diagnostic purposes (e.g., foreign body removal, hemostasis) or had bronchoscopy-related complications (e.g., severe hemorrhage, pneumothorax) that affected examination completion.\n* Duplicate Enrollment: Patients who were admitted multiple times for severe pneumonia during the study period; only the first admission is included to avoid duplicate data.",{"count":479,"type":23},400,"Severe pneumonia requires rapid and accurate diagnosis for targeted treatment, but single lung CT has limitations in identifying pathogens and distinguishing infectious\u002Fnon-infectious etiologies. This is a retrospective self-controlled study enrolling patients diagnosed with severe pneumonia at the institution between 2024 and 2025 (recruitment will be extended 6-12 months if fewer than 400 patients are enrolled), all of whom underwent both single lung CT and bronchoscopy-combined CT examinations.\n\nClinical data will be collected retrospectively, including demographic information, bronchoscopic mucosal findings (e.g., congestion, exudation), lung CT lesion characteristics (e.g., consolidation, ground-glass opacity), and gold standard diagnostic results (pathogenic detection or clinical comprehensive diagnosis). The core objective is to compare the diagnostic precision between single lung CT and bronchoscopy-combined CT, focusing on accuracy, sensitivity, and specificity across three etiological subtypes (bacterial\u002Ffungal, viral, non-infectious).\n\nBronchoscopy complements CT by directly visualizing airway mucosal changes, while CT provides panoramic views of pulmonary lesions. Their combination is hypothesized to improve diagnostic accuracy. The findings aim to optimize diagnostic strategies for severe pneumonia, guiding clinicians to select more effective imaging approaches.",[482],"Severe Pneumonia",[482,484,485,486,487],"Infectious Pathogen Identification","Bronchoscopic Imaging","Lung CT","Retrospective Cohort Study","2026-02-05",{"date":490,"type":32},"2026-02-09",{"date":67,"type":23},{"date":493,"type":23},"2026-12-31",{"name":38,"class":39},{"id":496,"slug":497,"hasResults":12,"nctId":498,"briefTitle":499,"officialTitle":500,"acronym":4,"eligibilityCriteria":501,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":502,"targetDuration":4,"studyType":125,"phases":504,"briefSummary":505,"conditions":506,"keywords":511,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":488,"lastUpdatePostDateStruct":518,"startDateStruct":519,"completionDateStruct":521,"leadSponsor":523,"locationsCount":40},"100606520","the-pre-vail-study-100606520","NCT07176624","The PRE-VAIL Study","The Effect of Reducing Enteral Nutrition Before Prone Positioning on Clinical Outcomes in Mechanically Ventilated ARDS Patients: A Multicenter Randomized Controlled Trial (The PRE-VAIL Study)","Inclusion Criteria:\n\n* Age ≥18 years old\n* Within 24 hours of admission to the ICU, one or more organ systems have failed (the Sequential Organ Failure Assessment (SOFA) score of any single organ system is ≥2)\n* Meet the diagnostic criteria for moderate\u002Fsevere ARDS (even after optimizing the ventilation Settings, the oxygenation index is still \\\u003C 150mmHg and PEEP is still ≥5 cm H2O)\n* It is expected to stay in the ICU for more than 48 hours\n\nExclusion Criteria:\n\n* There are contraindications for the prone position\n* There are contraindications for EN, preventing the initiation of early EN (≤48 hours)\n* Expected to die within 48 hours\n* Pregnancy",{"count":503,"type":23},259,[127],"During the prone position, there may be an increase in intragastric pressure. The investigators focus on a scientific question: Whether reducing enteral nutrition before the prone position will benefit patients with severe mechanically ventilated acute respiratory distress syndrome (ARDS).\n\nThe experimental group had the enteral nutrition dose reduced before the prone position, while the control group did not have the enteral nutrition dose reduced",[507,508,509,510],"ARDS (Moderate or Severe)","Prone Position","Enteral Nutrition Feeding","Intensive Care Unit (ICU) Admission",[512,513,514,515,516,517],"ARDS","Mechanical ventilation","Prone position","Enteral nutrition","Gastric retention","Clinical outcome",{"date":490,"type":32},{"date":520,"type":32},"2025-09-14",{"date":522,"type":23},"2028-02-20",{"name":38,"class":39},{"id":525,"slug":526,"hasResults":12,"nctId":527,"briefTitle":528,"officialTitle":529,"acronym":4,"eligibilityCriteria":530,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":531,"targetDuration":4,"studyType":125,"phases":533,"briefSummary":534,"conditions":535,"keywords":538,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":543,"lastUpdatePostDateStruct":544,"startDateStruct":545,"completionDateStruct":547,"leadSponsor":549,"locationsCount":40},"100623720","phase-2-sintilimab-combined-with-chemotherapy-for-adjuvant-treatment-of-mucosal-melanoma-after-surgery-100623720","NCT07400302","Sintilimab Combined With Chemotherapy for Adjuvant Treatment of Mucosal Melanoma After Surgery","A Randomized, Controlled, Multicenter Phase II Clinical Study Evaluating the Adjuvant Treatment of PD-L1-Positive, Resectable Mucosal Melanoma With Sintilimab Plus Chemotherapy Versus Chemotherapy Alone","Inclusion Criteria:\n\n1. Sign a written informed consent form (Informed Consent, ICF) and be able to comply with the visit schedule and related procedures outlined in the protocol.\n2. Histologically\u002Fcytologically confirmed mucosal melanoma, with primary and\u002For metastatic lesions completely resected, with negative surgical margins.\n3. Tissue specimen: PD-L1 positive (CPS ≥ 1).\n4. The first dose of the study drug must be administered only after the melanoma resection wound has fully healed, and the injection time must not exceed 13 weeks post-surgery (if the time limit is exceeded by no more than 7 days due to unforeseen circumstances, the decision to enroll may be discussed with the medical monitor).\n5. Confirmed R0 complete resection by physical examination and imaging within 4 weeks prior to randomization.\n6. For central nervous system (CNS) metastasis, post-surgical resection may receive adjuvant radiotherapy as needed. MRI of the brain must show no recurrence for at least 4 weeks after surgery or surgery combined with radiotherapy. Note: if immunosuppressants (e.g., prednisone) are required, they must be discontinued at least 14 days before the study drug administration.\n7. If lymph node dissection combined with local radiotherapy is required after melanoma resection, radiotherapy must be completed within 13 weeks of lymph node dissection and before the start of adjuvant treatment. Note: If delayed wound healing occurs due to radiotherapy, the subject will not meet the eligibility criteria.\n8. Age ≥ 18 years.\n9. Expected survival ≥ 12 weeks.\n10. Eastern Cooperative Oncology Group (ECOG) Performance Status (PS) score of 0 or 1.\n11. Sufficient organ and bone marrow function, with laboratory values meeting the following criteria within 7 days before enrollment (no blood components, cell growth factors, albumin, or other intravenous or subcutaneous corrective drugs should be given within 14 days prior to laboratory tests):\n\n(1) Hematology: Absolute Neutrophil Count (ANC) ≥ 1.5 × 10⁹\u002FL; Platelet Count (PLT) ≥ 90 × 10⁹\u002FL; Hemoglobin (HGB) ≥ 9.0 g\u002FdL (90 g\u002FL).\n\n(2) Liver Function: Total Bilirubin (TBIL) ≤ 1.5 × the upper limit of normal (ULN) (for patients suspected of or diagnosed with Gilbert's syndrome, TBIL ≤ 3 × ULN); Alanine Aminotransferase (ALT) and Aspartate Aminotransferase (AST) ≤ 2.5 × ULN.\n\n(3) Renal Function: Serum Creatinine (Scr) ≤ 1.5 × ULN, or Creatinine Clearance Rate (Ccr) ≥ 50 ml\u002Fmin (calculated using the Cockcroft\u002FGault formula), and urinalysis showing urinary protein (UPRO) \\\u003C 2+ or 24-hour urinary protein \\\u003C 1g.(Cockcroft-Gault Formula) (4) Coagulation Function: International Normalized Ratio (INR) and Prothrombin Time (PT) ≤ 1.5 × ULN.\n\n12\\. Female subjects of childbearing potential, or male subjects whose partners are women of childbearing potential, must use effective contraception throughout the treatment period and for 6 months after treatment.\n\nExclusion Criteria:\n\n1. Previous exposure to any anti-PD-1 or anti-PD-L1\u002F2 antibody.\n2. Previous use of interferon.\n3. Hyperthyroidism or hypothyroidism. Note: Hypothyroid patients whose condition is stable after hormone replacement therapy may be included.\n4. Concurrent participation in another clinical trial.\n5. Receipt of any investigational drug within 4 weeks before the first dose of the study drug.\n6. Use of immunosuppressive drugs within 4 weeks prior to the first dose of the study drug, excluding nasal, inhaled, or other topical corticosteroids or systemic corticosteroids at physiological doses (i.e., not exceeding 10 mg\u002Fday of prednisone or an equivalent dose of other corticosteroids).\n7. Receipt of live attenuated vaccines within 4 weeks before the first dose of the study drug or planned use during the study.\n8. Major surgery (e.g., craniotomy, thoracotomy, or laparotomy) or any unhealed wounds, ulcers, or fractures within 4 weeks before the first dose of the study drug.\n9. History of gastrointestinal perforation and\u002For fistulas within 6 months prior to the first dose of the study drug.\n10. Previous systemic anticancer treatment (e.g., chemotherapy, targeted therapy, or biologics). Chinese herbal medicine with anticancer indications or immunomodulatory drugs (e.g., thymosin, interleukins) are allowed after a 2-week washout period.\n11. Active, known, or suspected autoimmune diseases, or a history of autoimmune disease within the last 2 years (subjects with vitiligo, psoriasis, alopecia, or Grave's disease who did not require systemic treatment in the past 2 years, hypothyroidism requiring only thyroid hormone replacement therapy, and type 1 diabetes requiring only insulin replacement therapy may be included).\n12. Known history of primary immunodeficiency.\n13. Known history of organ transplantation (except corneal transplant) or hematopoietic stem cell transplant.\n14. History of idiopathic pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, drug-induced pneumonia, or any pulmonary diseases with severe impairment of lung function.\n15. Known history of severe allergic reactions to other monoclonal antibodies or interferons, or to any ingredient in the study drug (e.g., sintilimab or interferon).\n16. Clinically uncontrolled third-space fluid accumulation, such as pleural effusion or ascites that cannot be controlled by drainage or other methods before enrollment.\n17. HIV infection (HIV antibody positive).\n18. Acute or chronic active hepatitis B (HBV DNA copy number ≥ 1 × 10³ copies\u002Fml or ≥ 200 IU\u002Fml) or acute or chronic active hepatitis C (HCV antibody positive); patients with HCV antibody positive but RNA negative are eligible for inclusion.\n19. Active pulmonary tuberculosis.\n20. Active or clinically uncontrolled severe infections.\n21. Symptomatic congestive heart failure (NYHA Class III-IV) or symptomatic or uncontrolled arrhythmia.\n22. Uncontrolled hypertension despite appropriate treatment (systolic blood pressure ≥ 160 mmHg or diastolic blood pressure ≥ 100 mmHg).\n23. Any arterial thromboembolic event (e.g., myocardial infarction, unstable angina, pulmonary embolism, cerebral embolism) within 6 months before enrollment.\n24. History of deep vein thrombosis or any other severe thromboembolic event within 3 months before enrollment (implanted venous infusion ports or catheter-related thrombosis or superficial vein thrombosis are not considered \"severe\" thromboembolic events).\n25. Uncontrolled metabolic disorders or other non-malignant organ\u002Fsystemic diseases or cancer sequelae that would increase medical risks and\u002For create uncertainties in survival prognosis, and the investigator judges that the patient is unsuitable for enrollment.\n26. Hepatic encephalopathy, hepatorenal syndrome, or decompensated cirrhosis (Child-Pugh Class B or C).\n27. History of gastrointestinal perforation and\u002For fistulae, bowel obstruction (including incomplete bowel obstruction requiring parenteral nutrition), extensive bowel resection (e.g., partial colon or extensive small bowel resection resulting in chronic diarrhea), Crohn's disease, ulcerative colitis, or long-term chronic diarrhea within 6 months prior to enrollment.\n28. Other acute or chronic diseases, psychiatric disorders, or abnormal laboratory test results that may:\n\n(1) Increase the risk related to participation in the study or study drug administration.\n\n(2) Interfere with the interpretation of study results and lead the investigator to determine that the patient is ineligible for participation.\n\n29\\. History of other primary malignancies, excluding:\n\n1. Malignancies that have been cured with no evidence of active disease for at least 5 years prior to enrollment, with a very low risk of recurrence.\n2. Non-melanoma skin cancer or malignant lentigo maligna with no evidence of disease recurrence after sufficient treatment.\n3. In situ carcinoma that has been treated sufficiently with no evidence of recurrence.\n\n30\\. Pregnant or breastfeeding female patients. 31. Other conditions that, according to the investigator's judgment, make the patient unsuitable for participation in the study.",{"count":532,"type":23},220,[216],"Melanoma has emerged as the fastest-growing malignancy in recent years, with incidence and mortality rates among both men and women in East Asian countries exceeding the Asian average. China ranks fifth among East Asian nations in melanoma incidence. Currently, immune checkpoint inhibitors are achieving significant breakthroughs in adjuvant melanoma therapy. This study aims to evaluate the efficacy and safety of sintilimab combined with chemotherapy versus chemotherapy alone in patients with PD-L1-positive, completely resectable mucosal melanoma, thereby providing additional clinical evidence for treatment decisions.",[536,537],"Mucosal Melanoma","PD-L1 Positive",[539,540,541,542],"Adjuvant Treatment","PD-L1-Positive","Resectable Mucosal Melanoma","immunotherapy","2026-02-03",{"date":462,"type":32},{"date":546,"type":23},"2026-02-01",{"date":548,"type":23},"2029-09-30",{"name":38,"class":39},{"id":551,"slug":552,"hasResults":12,"nctId":553,"briefTitle":554,"officialTitle":555,"acronym":4,"eligibilityCriteria":556,"healthyVolunteers":12,"sex":18,"minAge":4,"maxAge":4,"enrollmentInfo":557,"targetDuration":4,"studyType":125,"phases":559,"briefSummary":560,"conditions":561,"keywords":564,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":566,"lastUpdatePostDateStruct":567,"startDateStruct":569,"completionDateStruct":571,"leadSponsor":573,"locationsCount":40},"100619589","effect-of-individualized-catheter-management-on-early-removal-after-rectal-cancer-surgery-100619589","NCT07346586","Effect of Individualized Catheter Management on Early Removal After Rectal Cancer Surgery","Effect of an Individualized Urinary Catheter Management Strategy on the Safety and Efficacy of Early Catheter Removal After Mid-Low Rectal Cancer Surgery: A Single-Center Randomized Controlled Trial","Inclusion Criteria:\n\n1. Patients with a preoperative pathological confirmation of rectal malignant tumor.\n2. Preoperative colorectal CT or rectal MRI confirming that the lower edge of the tumor is located in the rectum within 10 cm from the anal verge (including rectal and anal canal lesions).\n3. Patients scheduled to undergo laparoscopic or robot-assisted radical total mesorectal excision (TME).\n\nExclusion Criteria:\n\n1. History of previous abdominal surgery involving the rectum\u002Fsigmoid colon\u002Fleft colon, bladder resection or partial resection, prostate surgery (in males), or hysterectomy (in females).\n2. History of urethral trauma, intracranial surgery, spinal surgery, cerebral infarction with limb dysfunction, or Parkinson's disease.\n3. Inability to void urethrally preoperatively due to any reason (e.g., ureteral puncture, ureterostomy).\n4. Previously diagnosed overactive bladder syndrome, prior AUR or voiding dysfunction, or diabetic cystopathy.\n5. Preoperative assessment indicating potential need for combined resection of other pelvic organs during surgery, including the bladder, prostate, uterus and cervix, or vagina (excluding simple adnexectomy in females).\n6. Preoperative assessment indicating potential need for lateral pelvic lymph node dissection.\n7. Preoperative renal insufficiency (serum creatinine level \\>133 μmol\u002FL).\n8. Patients undergoing emergency surgery.\n9. Male patients with preoperative benign prostatic hyperplasia requiring medication.\n10. Presence of indwelling ureteral stents, ureteral stenosis, or bilateral hydronephrosis.",{"count":558,"type":23},1545,[127],"This study aims to systematically evaluate the safety and efficacy of different early urinary catheter removal strategies following radical resection of mid-low rectal cancer. Current clinical practice faces controversy regarding the optimal timing of catheter removal (24 hours vs. 48 hours) and lacks precise preventive measures for patients at high risk of postoperative acute urinary retention (AUR). To address these issues, this study is designed as a three-arm randomized controlled trial, directly comparing three management protocols: catheter removal at 24 hours postoperatively, catheter removal at 48 hours postoperatively, and an individualized strategy guided by a predictive model (i.e., preventive administration of tamsulosin to high-risk AUR patients prior to catheter removal). The primary endpoint is the rate of recatheterization within 7 days after the initial removal, with secondary endpoints comprehensively assessing urinary tract infections, voiding function, and postoperative complications. The ultimate goal is to provide high-quality evidence-based medical evidence to establish a precise and standardized clinical pathway for individualized postoperative catheter management.",[562,263,563],"Urinary Catheters","Urinary Retention",[563,263,565],"Catheter","2026-01-08",{"date":568,"type":32},"2026-01-16",{"date":570,"type":23},"2026-02-20",{"date":572,"type":23},"2029-12-20",{"name":38,"class":39},{"id":575,"slug":576,"hasResults":12,"nctId":577,"briefTitle":578,"officialTitle":579,"acronym":4,"eligibilityCriteria":580,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":581,"targetDuration":4,"studyType":125,"phases":583,"briefSummary":584,"conditions":585,"keywords":587,"overallStatus":28,"whyStopped":4,"lastUpdateSubmitDate":591,"lastUpdatePostDateStruct":592,"startDateStruct":594,"completionDateStruct":596,"leadSponsor":598,"locationsCount":40},"100519561","early-tirofiban-administration-after-intravenous-thrombolysis-in-acute-ischemic-stroke-100519561","NCT06045156","Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke","Early Tirofiban Administration After Intravenous Thrombolysis in Acute Ischemic Stroke: A Multicenter, Randomized, Double-blind, Placebo-controlled Clinical Trial","Inclusion Criteria:\n\n1. Age≥18 years old;\n2. Clinically diagnosed as acute ischemic stroke and received standard dose (0.25mg\u002Fkg) of tenecteplase IVT within 4.5 hours of onset;\n3. Total National Institute of Health stroke scale (NIHSS)≥4 or single limb motor item score≥2, and total NIHSS≤15 after IVT;\n4. Tirofiban or placebo treatment can be initiated within 6h after IVT;\n5. mRS score before onset≤ 1;\n6. Intracranial hemorrhage is ruled out by CT head after IVT;\n\nExclusion Criteria:\n\n1. Received or plan to undergo bridge therapy;\n2. Large area of infarct indicated by radiological imaging(≥1\u002F3 of middle cerebral artery supply area);\n3. Atrial fibrillation or suspected cardiac embolism;\n4. Accompanied by epileptic seizures;\n5. Using antiplatelet, anticoagulant or fibrinolytic agents within 24h before recruitment;\n6. Active bleeding or tendency to bleed after receipt of intravenous thrombolysis;\n7. Digestive system bleeding, urinary system bleeding, hemorrhagic retinopathy or other systemic bleeding events within 1 year;\n8. Severe renal or liver insufficiency; ALT or AST\\>3 times of the upper limit of normal value or above; creatinine clearance rate\\\u003C30 mL\u002Fmin, creatinine\\>200μmol\u002FL；\n9. Life expectancy less than 3 months;\n10. Pregnant or lactating women;\n11. Known allergy to tirofiban;\n12. Being enrolled or having been enrolled in other clinical trial within 3 months prior to this clinical trial.;\n13. Patients who are unwilling to be followed up or likely to have poor treatment compliance;\n14. Other situations that the researcher deems unsuitable for inclusion in the study.",{"count":582,"type":23},1084,[127],"The purpose of this study is to evaluate the efficacy and safety of early tirofiban administration in patients undergoing IVT",[586],"Acute Ischemic Stroke",[588,589,590],"acute ischemic stroke","intravenous thrombolysis","tirofiban","2025-12-22",{"date":593,"type":32},"2025-12-30",{"date":595,"type":32},"2024-04-29",{"date":597,"type":23},"2026-12-30",{"name":38,"class":39},{"id":600,"slug":601,"hasResults":12,"nctId":602,"briefTitle":603,"officialTitle":604,"acronym":4,"eligibilityCriteria":605,"healthyVolunteers":12,"sex":18,"minAge":19,"maxAge":4,"enrollmentInfo":606,"targetDuration":4,"studyType":125,"phases":608,"briefSummary":609,"conditions":610,"keywords":4,"overallStatus":62,"whyStopped":4,"lastUpdateSubmitDate":612,"lastUpdatePostDateStruct":613,"startDateStruct":615,"completionDateStruct":617,"leadSponsor":619,"locationsCount":4},"100616460","efficacy-and-safety-of-minocycline-in-the-treatment-of-intracerebral-hemorrhage-100616460","NCT07305896","Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage","Efficacy and Safety of Minocycline in the Treatment of Intracerebral Hemorrhage: a Multicenter, Randomized, Open-label, Blinded Endpoint Clinical Study","Inclusion Criteria:\n\n1. Age ≥ 18 years, regardless of gender;\n2. Supratentorial ICH confirmed by brain CT scan;\n3. No disability in the community before ICH (premorbid mRS≤1);\n4. Neurological deficits related to the hematoma, with NIHSS score ≥ 6 and single-limb motor item score ≥ 2;\n5. GCS score ≥ 6;\n6. Able to initiate the first dose of minocycline within 24 hours of onset;\n7. Signed and dated informed consent.\n\nExclusion Criteria:\n\n1. Definite evidence of secondary ICH, such as structural abnormality, brain aneurysm, brain tumor, use of thrombolytic drugs;\n2. Allergy to tetracycline antibiotics;\n3. Use of vitamin A derivatives or steroid therapy within the past 3 months;\n4. Concomitant infection requiring antibiotic treatment at admission;\n5. Planned surgical intervention;\n6. Life expectancy of less than 6 months due to comorbid conditions;\n7. Severe hepatic and renal dysfunction, or AST and\u002For ALT \\>3 times the upper limit of reference range, or serum creatinine \\>265 μmol\u002FL (\\> 3 mg\u002FdL);\n8. Bleeding tendency, including heparin use within the past 48 hours (APTT ≥ 35 s), oral warfarin (INR \\> 2), platelet count \\\u003C 100 × 10⁹\u002FL, or hereditary hemorrhagic diseases;\n9. Known pregnancy or breastfeeding;\n10. Patients being enrolled or having been enrolled in another clinical trial within the 3 months prior to this clinical trial;\n11. A high likelihood that the patient will not adhere to the study treatment and follow-up regimen;\n12. Patients unsuitable for enrollment in the clinical trial according to the investigator's discretion.",{"count":607,"type":23},1248,[127],"This study plans to enroll 1248 patients with supratentorial ICH within 24 hours of onset across multiple stroke centers. After randomization, the control group will only receive medical therapy. The experimental group, after randomization, will receive an initial dose of 200 mg of minocycline hydrochloride capsules in addition to medical ttherapy, followed by 100 mg orally every 12 hours for 7 days, resulting in a total of 14 administrations. Both groups will be followed for 180 days to evaluate the efficacy and safety of minocycline in the treatment of ICH.",[611],"Intracerebral Hemorrhage","2025-12-14",{"date":614,"type":32},"2025-12-26",{"date":616,"type":23},"2025-12-31",{"date":618,"type":23},"2028-12-31",{"name":38,"class":39},""]